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ABSTRACT  
Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous 
system (CNS) that is characterized by a variable clinical course and heterogeneous 
and complex pathology. Pathophysiological processes in MS contribute to the 
disease course and clinical manifestations, and therefore biomarkers that are 
indicative of these events would provide significant potential for diagnostics, 
prediction of disease course and optimization of therapeutic responses. 
The goal of this thesis was to identify biomarkers in the blood that could reflect 
pathogenetic processes in MS and be used as biomarkers of disease activity and 
progression. In this regard, the aims were to: 1) define immune profiles in different 
clinical subtypes of MS and clinically isolated syndrome (CIS); 2) search for 
biomarkers for disease activity and disability; 3) search for prognostic biomarkers for 
CIS to MS, and 4) explore whether the postpartum disease activation of MS is related 
to changes in the apoptotic molecules in the blood. The study included patients with 
different subtypes of MS, CIS and healthy controls that underwent neurological, 
magnetic resonance imaging (MRI) and immunological examinations. 
Altered expression of immune profiles in MS subtypes were found on both the 
protein and gene levels. Immune profiles in sera of primary progressive MS (PPMS) 
were characterized by elevated levels of tumor necrosis factor (TNF)-?, soluble Fas 
(sFas) and C-C chemokine motif ligand 2 (CCL2).  Decreased serum levels of 
macrophage migration inhibitory factor (MIF) were found in relapsing-remitting MS 
(RRMS). Aberrant expression of six apoptosis-related genes (BAD, BBC3, BCL2L14, 
TNFRSF25, IKBKE, NFKBID), including B-cell lymphoma 2 (Bcl-2) and nuclear 
factor kappa B (NF-?B) families and death receptor pathway, were found in RRMS 
patients. Interestingly, atypical expression profiles of apoptosis-related genes were 
also seen in CIS (BNIP3, TNFRSF25, IKBKE).  
Active disease course was associated with upregulation of serum MIF and TNF-
related apoptosis inducing ligand (TRAIL), and disease progression was associated 
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with increased TRAIL mRNA, MIF and sTRAIL. In CIS, elevated expression of 
three apoptosis-related genes (APAF, BIRC6, CFLAR) was found in those patients 
who fulfilled the diagnostic criteria for MS over the two-year follow up.  
In the study of the immunomodulatory effect of pregnancy on MS, sTRAIL and 
sFasL were upregulated in both MS patients and healthy women from late pregnancy 
to postpartum. The increase in sTRAIL was significantly smaller in the MS patients 
in comparison with the controls.  
In summary, this thesis focusing on the identification of biomarkers in MS 
showed that PPMS was characterized by elevated levels of TNF-?, sFas and CCL2 
indicating inflammatory activity in this subtype. Abnormal expression of apoptosis-
related genes in RRMS and CIS suggested an enhanced potential for apoptosis in 
immune cells directed at controlling MS disease activity. Disease activity was 
associated with increased levels of serum TRAIL and MIF and disease progression 
was associated with upregulated levels of sFas, MIF and TRAIL mRNA, suggesting 
these molecules to be candidate biomarkers for disease activity and progression. 
Interestingly, three new prognostic biomarkers for conversion to MS were found. 
Increased MS disease activity postpartum may be related to inadequate inhibition of 
T-cell reactivation after pregnancy. Currently we are validating these findings using 
larger patient series and longer follow-up periods. 
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TIIVISTELMÄ  
Multippeliskleroosi (MS) alkaa nuorella aikuisiällä ja johtaa vuosien kuluessa 
invaliditeetin kertymiseen. Sairauden syytä ei toistaiseksi tunneta, mutta sen 
kliinisessä kuvassa ja patogeneesissä esiintyy monimuotoisuutta ja yksilökohtaista 
vaihtelua. Tärkeänä tavoitteena MS-taudin hoidon kehittämisessä on tunnistaa 
sairauden immunologiset alatyypit, joka edistäisi yksilöllisen hoidon edellytyksiä ja 
täsmälääkkeiden käyttöönottoa. 
Väitöskirjatyön päätavoitteena oli tunnistaa taudin patogeneesiä kuvaavia veren 
immunologisia profiileja MS-taudin eri alatyypeissä. Lisäksi tutkimuksen tavoitteena 
oli identifioida biomerkkiaineita, jotka kuvaavat taudin aktiivisuutta ja sen 
etenemistä ja jotka ennustaisivat MS-taudin kehittymisen riskiä, sekä selvittää onko 
MS-taudin aktivoituminen synnytyksen jälkeen yhteydessä muutoksiin 
apoptoottisten molekyylien ilmentymisessä. Tutkimus koostui MS-potilaita, 
kliinisesti eriytyneestä oireyhtymästä (KEO) ja terveistä kontrolleista, jotka tutkittiin 
neurologisesti ja aivojen kuvantamisella sekä heidän verinäytteistä tutkittiin 
ehdokasbiomerkkiaineiden ilmentymisprofiileja. 
MS-taudissa poikkeavia immuniprofiileja ilmentyi sekä proteiini- että 
geenitasolla. Primaarisprogressivisessa MS-taudissa havaittiin kohonneita TNF-?, 
Fas ja CCL2 pitoisuuksia. Lisäksi havaitsimme Bcl-2 ja NF-?B perheiden ja 
kuolemareseptori signalointireitille kuuluvien kuuden geenin yli-ilmentyneen 
aaltomaisessa MS-taudissa. Myös KEO-potilailla havaittiin poikkeavuutta 
apoptoottisten geenien ilmentymisessä. Aaltomaisen MS-taudin aktiivisuus liittyi 
TRAIL ja MIF proteiinien pitoisuuksien lisääntymiseen. Invaliditeetin lisääntyminen 
oli puolestaan yhteydessä kohonneisiin TRAIL mRNA pitoisuuksiin, sekä 
kohonneisiin seerumin MIF ja Fas pitoisuuksiin. Lisäksi, kolmen geenin 
ilmentyminen havaittiin olevan koholla niillä KEO-potilailla, joilla MS-diagnoosi 
varmentui kahden vuoden seurannan aikana. Tutkimuksessa raskauden 
immunomoduloivasta vaikutuksesta MS-taudin aktiivisuuteen havaittiin seerumin 
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TRAIL ja FasL:n tasojen kasvavan raskauden aikaisesta synnytyksen jälkeiseen 
tilaan sekä MS-potilailla että terveillä naisilla. Seerumin TRAIL:n muutoksen 
havaittiin olevan pienempi MS-potilailla kuin terveillä. 
Tämän väitöskirjatutkimuksen tavoitteena oli tunnistaa MS-taudin seurantaan 
soveltuvia biomerkkiaineita. Kohonneet seerumin TNF-?, Fas ja CCL2 pitoisuudet 
primäärisprogressiivisessa MS-taudissa kuvastivat meneillään olevaa tulehduksellista 
aktiivisuutta tässä tautityypissä. Apoptoottisten geenien poikkeavat 
ilmentymisprofiilit aaltomaisilla ja KEO potilailla viittaa lisääntyneisiin 
apoptoottisiin mekanismeihin taudin aktiivisuuden hillitsemiseksi. Uusia kandidaatti 
biomerkkiaineita havaittiin, joista kohonneet TRAIL ja MIF tasot saattavat olla 
yhteydessä aaltomaisen taudin aktiivisuuteen, kun taas kohonneet Fas ja MIF 
proteiinien tasot ja TRAIL mRNA:n ilmentyminen invaliditeetin kertymiseen. 
Lisäksi useita ennustavia kandidaattibiomerkkiaineita löydettiin, joiden yli-
ilmentyminen näyttää olevan yhteydessä MS-taudin kehittymisen riskiin. Lisääntynyt 
MS-taudin aktiivisuus raskauden jälkeen selittyneen häiriöinä immuunijärjestelmän 
aktivaatiota säätelivissä mekanismeissa. Saatujen tuloksien varmentaminen edellyttää 
suurempaa potilasaineistoa sekä pidempää seuranta-aikaa. 
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INTRODUCTION  
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central 
nervous system (CNS), where the pathological hallmarks are demyelination, axonal 
loss and inflammation (Trapp and Nave, 2008; Lassmann, 2009; Stadelmann, 2011). 
MS is the major cause of the neurological disability in young adults and therefore it 
has substantial personal, social and economic costs. MS is highly prevalent in 
northern countries, particularly in Finland where the prevalence of MS is among the 
highest in the world (Compston, 1997; Sumelahti et al., 2001). 
MS is characterized by a variable clinical course and heterogeneous and complex 
pathology and pathogenesis. There are three clinical subtypes of MS involving 
relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary 
progressive MS (PPMS). Most patients initially have RRMS, which is characterized 
by relapses followed by subsequent improvement. After 10 to 20 years of RRMS, a 
majority of these patients will enter a phase of progression with or without attacks, 
called SPMS. A minority of patients (15%) have PPMS from onset. These patients’ 
disease progresses slowly without relapses (Lublin and Reingold, 1996; Compston 
and Coles, 2002). The underlying pathological mechanism involved in CNS 
destruction is also heterogeneous. Currently pathological studies have suggested four 
different immunopathological patterns in demyelination in early MS lesions, which 
differ between patients. Although MS is considered to be as a white matter disease, 
grey matter is also affected (Lucchinetti et al., 2000; Lassmann et al., 2001; 
Lassmann et al., 2007). 
MS disease is considered to be mediated by actions of inflammatory lymphocytes, 
which transmigrate into the CNS and initiate tissue damage and neurological 
impairment. Based on the current understanding, autoimmune-driven processes are 
believed to initiate the disease and the role of myelin specific CD4+ T helper (Th) 
cells type 1 and Th17 cells as driving force in the autoimmune processes, but also 
other cell types like, CD8+ T cells, B cells, macrophages and natural killer (NK) 
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cells contributes to the pathogenesis of MS (Sospedra and Martin, 2005; Kasper and 
Shoemaker, 2010). Programmed cell death, apoptosis of immune cells, is also an 
important pathophysiological mechanism in MS inflammation. It regulates 
elimination of autoreactive T and B cells and macrophages from the circulation and 
prevents their entry into the CNS. Dysregulation of apoptosis and other immune 
functions may lead to inflammation within CNS tissue and subsequent development 
of tissue damage (Zipp, 2000; Pender, 2007). 
Several pathophysiological processes such as inflammation, demyelination and 
axonal damage mediate disease manifestation of MS. Since future therapeutic agents 
will probably be targeted specifically on pathophysiological pathways, the 
identification of possible immunological subtypes of individual MS patients could 
allow more focused application of different therapies (Lutterotti et al., 2007). 
Therefore, there is urgent need for an in vivo biomarker that would reflect underlying 
immunopathogenesis in MS patients. Moreover, the ultimate goal in the discovery of 
biomarkers in MS is to develop tools to predict disease outcome, to assess disease 
activity more accurately, and to predict therapeutic responses. 
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REVIEW OF THE LITERATURE  
1. Overview of multiple sclerosis  
1.1 Epidemiology of multiple sclerosis 
The etiology of MS is still largely unknown, but there is evidence for a role of both 
genetics and environmental factors (Figure 1) (Ramagopalan et al., 2010). It is 
suspected that an infectious agent may trigger the disease in genetically susceptible 
individuals. The geographic distribution of MS is an epidemiological hallmark of it. 
In general, the prevalence of MS is lower in populations living near the equator and 
increases with the latitude in both the northern and southern hemispheres. The 
disease is most common in populations of northern European descent, especially in 
Scandinavia, the British Isles, the northern tier of the United States and southern 
Canada (Compston, 1997). In these regions the prevalence of MS is about 100/100 
000. In certain parts of Finland the prevalence is 200/100 000 (Sumelahti et al., 2000; 
Sumelahti et al., 2001). 
Genetic factors: The role of the genetic factors is supported by the studies of MS 
families. Concordance rates have been 20-30% in monozygotic twins versus 3-5% in 
dizygotic twins in these populations (Sadovnick et al., 1993). Siblings have a 15-40 
fold increase risk of having MS and there is no effect of shared environment in 
adoptees and spouses (Ebers et al., 1995; Robertson et al., 1996; Sadovnick et al., 
1996; Ebers et al., 2000). Among the genetic factors, the human leukocyte antigen 
(HLA) DRB1*1501 allele exerts the strongest genetic effect on MS (Barcellos et al., 
2006; Yeo et al., 2007).  Genome-wide association studies have revealed the 
existence of multiple non-HLA genes with modest effect on MS, including 
interleukin-7 receptor ? (IL7RA), interleukin-2 receptor ? (IL2RA), C-type lectin-
17 
domain family 16 member A (CLEC16A), lymphocyte function-associated antigen-3 
(LFA-3; CD58), tumor-necrosis-factor receptor superfamily member 1A 
(TNFRSF1A), interferon regulatory factor 8 (IRF8) and CD6 (International Multiple 
Sclerosis Genetics Consortium et al., 2007; Ramagopalan et al., 2007; International 
Multiple Sclerosis Genetics Consortium (IMSGC), 2008; Rubio et al., 2008; De 
Jager et al., 2009). 
 
 
Figure 1. Complex nature of multiple sclerosis. 
Environmental factors: Epidemiological and immigration studies have 
suggested that not only genetics factors, but also environmental factors increase the 
risk of developing MS (Kurtzke, 1993). Large-scale immigrant studies have shown 
that the risk of MS decreases, if children migrate from a high- to a low-risk region 
and the risk increase when children migrate from a low- to a high-risk region. Factors 
with the strongest evidence for involvement in MS are virus infections such as 
Epstein-Barr virus (EBV), the influenza A virus, smoking and vitamin D deficiency 
18 
(Milo and Kahana, 2010; Oikonen et al., 2011). Almost all individuals with MS 
(>99%) have been found to have been infected with EBV in comparison to age-
matched controls (94%). MS is rare who have not been infected with EBV (Thacker 
et al., 2006; Ramagopalan et al., 2010). Sunlight exposure and vitamin D deficiency 
are the potential explanations for the associations between latitude and MS 
incidence. Sun exposure in childhood protects against MS (van der Mei et al., 2003; 
Islam et al., 2007; Kampman et al., 2007). Low serum levels of vitamin D are 
associated with a higher risk of developing MS (Munger et al., 2006; Lucas et al., 
2011). Low vitamin D levels have been associated with an increased risk of relapses 
(Soilu-Hanninen et al., 2005; Smolders et al., 2008b; Simpson et al., 2010). Vitamin 
D has an immunoregulatory functions. It inhibits CD4+ T cell proliferation and the 
production of proinflammatory cytokines and stimulates production of anti-
inflammatory cytokines (Smolders et al., 2008a). Smoking has been shown to 
increase the risk of MS and therefore promoting smoking cessation would be one of 
the most straightforward interventions available to reduce the incidence of MS 
(Hawkes, 2007). 
Gender-related hormones: MS is more common in women than in men (Wallin 
et al., 2004; Orton et al., 2006; Alonso and Hernan, 2008; Hirst et al., 2009), but 
genome-wide studies have not found any MS-associated genes in the X chromosome. 
Therefore, the increased incidence of MS in women might be related with female-
specific physiology and could thus be hormone related (Whitacre, 2001; Voskuhl, 
2011). Sex hormones (estrogens, progestins, androgens) have been shown to 
modulate immune responses, as well as brain damage (Tomassini and Pozzilli, 
2009). Especially estradiols and testosterone play an important modulatory role in 
MS brain damage. 
Pregnancy provides another example of changes in hormonal patterns that 
influence clinical disease activity as well as subclinical disease activity. The 
Pregnancy in Multiple Sclerosis (PRISM) study was the first large prospective study 
that aimed at assessing the possible influence of pregnancy and delivery on the 
clinical course of MS (Vukusic et al., 2004). The study showed reduction in the 
relapse rate during pregnancy, especially in the third trimester, in comparison to the 
year before pregnancy. In the first three months postpartum the relapse rate increased 
compared to the pre-pregnancy state. Two years after delivery, the annualized relapse 
rate did not differ significantly from the pre-pregnancy rate. The effect of pregnancy 
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on MS disease activity has been explained by changes in the mother’s endocrinal and 
immune system such as an increase in the levels of the sex hormones estrogen and 
progesterone together with a shift of in maternal immune responses from a prevailing 
Th1 to Th2 type responses (Nicot, 2009). A decrease in circulating NK cells and an 
increase in regulatory T cells (Treg) during pregnancy has been associated with 
reduced MS disease activity (Somerset et al., 2004; Saraste et al., 2007). Especially, 
an increase in circulating regulatory CD56(bright) NK cells and a decrease in 
circulating cytotoxic CD56(dim) NK cells in late pregnancy was considered to be 
associated with inhibition of MS activity during pregnancy (Airas et al., 2008). 
 
 
 
Figure 2. Progression of MS from RRMS to SPMS. Top: schematic representation 
of the disability progression expressed by expanded disability status scale 
(EDSS, violet line); frequency of inflammatory events when studied by 
magnetic resonance imaging: detection of Gadolinium (Gd)-contrast 
enhancing T1 lesions showing blood-brain barrier (BBB) opening (orange 
arrows); T2 lesion load reflecting brain tissue loss (orange line); brain 
volume indicative of brain atrophy (blue line). Pathology: in the early stage 
of the disease inflammation predominates whereas neurodegeneration is 
more pronounced at the later stages. On the left, perivascular 
inflammation with mononuclear cells, and on the right, axonal loss and 
demyelination. Therapies: in the early phase immunomodulatory 
therapies, which are targeted to decrease the inflammation are efficient, 
and in the later stage therapies, which protect the neurons would be 
beneficial. Redrawn from Sospedra and Martin 2005. 
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1.2 Clinical subtypes  
MS has very heterogeneous clinical presentations and courses (Noseworthy et al., 
2000). MS is classified on the basis of both the initial and the current clinical disease 
course (Figure 2 and 3). Most patients (85%) initially have RRMS, which is 
characterized by discrete clinical attacks or relapses followed by subsequent 
improvement. During these episodes of inflammation, clinical attacks typically 
develop over several days, become maximal after 1 to 2 weeks, and gradually resolve 
themselves over several weeks or months. RRMS is the most typical presentation in 
younger patients. After 10 to 20 years of RRMS, a majority of RRMS patients will 
enter a phase of progression with or without attacks, called SPMS. Figure 2 
demonstrates disease development from RRMS to SPMS. A minority of patients 
(15%) have PPMS course from onset. These patients’ disease progresses slowly 
without relapses. This subtype is considered to be a mostly noninflammatory 
subtype. (Lublin and Reingold, 1996; Compston and Coles, 2002) 
The majority of patients with MS present in a relapsing-remitting fashion and 
their first attack presents as unilateral optic neuritis, a brainstem syndrome or partial 
myelitis. These presentations are known as clinically isolated syndrome (CIS) (Miller 
et al., 2005). Several placebo-controlled clinical trials on the efficacy of interferon 
(IFN)-? or glatiramer acetate (GA) have showed that majority of patients converted 
to MS during the two and three year follow-up (Jacobs et al., 2000; Comi et al., 
2001; Kappos et al., 2006; Kinkel et al., 2006; Kappos et al., 2007; Comi et al., 
2009)  
1.3 Diagnosis 
Diagnostic criteria for MS are mainly based on clinical evaluation, although this is 
facilitated by supportive laboratory and radiological investigations. During the last 
fifty years, various diagnostic criteria have been used (Schumacker et al., 1965; 
Poser et al., 1983; McDonald et al., 2001; Polman et al., 2005). In the beginning, the 
Schumacker criteria were based on clinical evidence of two relapses that were 
separated in space (lesions in the different locations in the CNS) and time (at least 
three months apart) (Schumacker et al., 1965). These criteria were updated in 1983 
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by the Poser criteria, which allow using also paraclinical evidence such as magnetic 
resonance imaging (MRI), oligoclonal band (OCB) analysis from cerebrospinal fluid 
(CSF) and visual evoked potential analysis (Poser et al., 1983). Eighteen year later 
the diagnostic criteria were updated by the McDonald criteria, which underline the 
importance of MRI in the diagnosis that allows earlier diagnosis of patients at their 
first episode (McDonald et al., 2001). The McDonald criteria were revised in 2005 
and the changes mainly focus on the use of T2-weighted lesions and spinal cord 
imaging (Polman et al., 2005). 
 
 
Figure 3. Clinical subtypes of MS. Redrawn from Lublin and Reingold 1996. 
1.4 Disease-modifying therapies of multiple sclerosis 
A number of disease-modifying therapies (DMT) with partial efficacy for patients 
with RRMS became available during the past 20 years. All of these drugs mainly 
target the inflammatory component of the diseases (Table 1). All the DMTs have 
shown to be effective in the RRMS type, but not in the PPMS. The most commonly 
used therapies that are approved for RRMS include the type-1 beta IFNs and GA 
(Table 1) (Barten et al., 2010). Several follow-up studies have evaluated the efficacy 
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of DMTs in MS, and it has been shown that treatments decrease the relapse rate and 
reduce the number of MRI lesions (The IFNB Multiple Sclerosis Study Group, 1993; 
Johnson et al., 1995; Jacobs et al., 1996; PRISMS Study Group, 1998). Also DMTs 
over a long period of time improves outcome by delaying the time to significant 
disease progression (Freedman, 2011). 
Table 1. Current therapies for MS 
Therapy Mechanism of action Developmental 
phase 
 Ref 
First-line therapy 
 
  
Interferon-? Inhibit T-cell activation and reduce 
blood-brain barrier (BBB) permeability 
to inflammatory cells. 
 
Approved 
therapy for MS 
 1 
Glatiramer acetate Immune modulator and it is thought to 
shift the immune responses from T 
helper (Th) 1 to Th2 type. 
Approved 
therapy for MS 
 2 
Second-line therapies  
 
  
Natalizumab Blocks very late antigen-4 (VLA-4) on 
the surface of lymphocytes and 
therefore reduce the transmigration of 
inflammatory lymphocytes via BBB 
into the CNS. 
 
Approved 
therapy for MS 
 3 
Mitoxantrone Immunosuppressive cytotoxic agent 
that inhibits B-cell, T-cell, and 
macrophage proliferation and impairs 
antigen presentation and production of 
proinflammatory cytokines. 
 
Approved 
therapy for MS 
 4 
Fingolimod  Blocks sphingosine-1-phosphates 
receptors in T cells that results in an 
inhibition of T-cell migration from 
lymphoid tissue into the peripheral 
circulation and CNS. 
Approved 
therapy for MS 
 4 
Promising new drugs 
 
 
 
  
Cladribine 
 
Purine nucleoside analog that 
produces selective lymphocyte 
depletion through the inhibition of 
cellular DNA synthesis and repair. 
 
Phase III 
completed 
 5 
Laquinimod Immunomodulatory molecule that 
favors Th2/Th3 cytokine production 
and inhibits immune cell 
transmigration into the CNS. 
 
Phase III 
ongoing 
 5 
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Teriflunomide Inhibitor of dihydroorotate 
dehydrogenase, which is an integral 
membrane protein for pyrimidine 
synthesis. Inhibition of the enzyme 
prevents the clonal expansion of B and 
T cells and antibody production. 
 
Phase III 
completed 
 4 
Dimethyl fumarate Anti-inflammatory and neuroprotective 
effects 
Phase III  6 
Alemtuzumab Humanized monoclonal antibody 
directed against CD52 antigen on T 
cells and B lymphocytes, monocytes, 
macrophages, natural killer cells. 
Phase III  6 
     
Rituximab First generation monoclonal antibody 
against the CD70 antigen on B cells 
that effectively depletes B cells via 
complement-dependent cell lysis and 
antibody dependent cellular toxicity. 
 
Phase II/III  7 
Ocrelizumab Humanized monoclonal antibody 
against CD70. 
 
Phase III  8 
Ofatumumab Fully human monoclonal antibody 
against CD70 antigen. 
 
Phase III  8 
Daclizumab Monoclonal antibody directed against 
? subunit of interleukin-2 receptor 
(CD25) on activated T cells, which 
limits T-cell activation. 
Phase III  6 
1) Markowitz, 2007; 2) Farina et al., 2005; 3) Steinman, 2005; 4) Nicholas et al., 2011; 5) 
Fox, 2010; 6) Lim and Constantinescu, 2010; 7) Buttmann and Rieckmann, 2008; 8) 
Buttmann, 2010. 
 
IFNs are the cytokines that are normally released from the lymphocytes in 
response to pathogens. There are three types of interferons: IFN-?, -? and -?. IFN-? 
is approved for the treatments of MS. Its mechanism of action is not fully 
understood, but it has been shown to inhibit T-cell proliferation, reduce T-cell 
migration from the periphery to the CNS, and alter the T cell cytokine secretion 
toward anti-inflammatory responses (Markowitz, 2007). In clinical practice three 
different IFN-? preparations are available, in which dose and frequency of 
administration differ. 
GA is a synthetic polypeptide (40-100 amino acids) composed of random 
sequences of four amino acids (tyrosine, glutamate, alanine, and lysine), which are 
common in myelin basic protein (MBP). GA clinical efficacy has been explained by 
a shift of proinflammatory responses towards anti-inflammatory responses (Farina et 
al., 2005; Johnson, 2010).  
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Currently, several potential therapeutic agents are being examined in ongoing 
phase II and III clinical trials (Table1). For example Alematzumab, Daclizumab and 
Rituximab are monoclonal antibodies targeting CD52+ T cell, CD25+ NK and T 
cells and CD20+ B cells, respectively (Buttmann and Rieckmann, 2008; Barten et al., 
2010; Nicholas et al., 2011). 
2. Pathogenesis and neuropathology  
2.1 Neuropathology of multiple sclerosis 
Pathologically MS is characterized by the presence of large, multifocal, 
demyelinated CNS lesions in multiple areas leading to scar tissue called sclerosis. 
This demyelination process is accompanied by autoimmune inflammatory reactions 
that are mediated mainly by T cells, B cells and macrophages. Primary targets are the 
myelin sheaths and oligodenrocytes, but axons, nerve cells and astrocytes are also 
affected (Frohman et al., 2006; Trapp and Nave, 2008). 
The lesions observed in the CNS of MS patients are typically characterized by a 
demyelinated core separated by a very sharp border from normally myelinated 
surrounding tissue (Frohman et al., 2006). Many white matter lesions are detected in 
certain predilection sites, notably around the ventricles. Other predilection sites 
include the optic nerve and spinal cord. Moreover, lesions may also occur in the deep 
white matter far from ventricles as well as grey matter (Lassmann et al., 2007). The 
white matter lesions can be characterized broadly as chronic and active lesions. In 
chronic lesions there are less mononuclear cells, almost complete demyelination and 
severe astrogliosis. Active lesions are defined by ongoing destruction of myelin and 
are heavily infiltrated by macrophages and microglial cells (Frohman et al., 2006). 
Clinical and MRI data suggest that inflammation and formation of new white 
matter lesions are the substrate for RRMS.  In the progressive phase the new 
inflammatory demyelinating lesions are rare, but diffuse atrophy of the grey and 
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white matter and changes in the normal-appearing white matter (NAWM) are more 
predominant (Lassmann et al., 2007). Although MS is considered to be inflammatory 
demyelinating disease of the CNS, axonal injury and loss also occurs in the MS 
lesions and is associated with the development of permanent disability in MS 
patients (Trapp et al., 1998; Bjartmar et al., 2000). This suggests that progressive 
axonal loss may induce transition from RRMS to SPMS. Axon pathology and the 
frequency of transected axons in MS lesion correlate with the degree of inflammation 
(Frischer et al., 2009).  
Normal appearing white matter may consider highly abnormal in MS patients, 
especially in patients in the progressive stage of the disease (Allen and McKeown, 
1979; Kutzelnigg et al., 2005). Changes in the NAWM consist of a diffuse 
inflammatory process. Inflammatory infiltrates are present in the perivascular space 
and are also dispersed throughout the tissue. Inflammation is associated with 
profound microglia activation. This microglia activation is associated with diffuse 
axonal injury and loss (Kutzelnigg et al., 2005). The mechanisms that lead to diffuse 
injury of the NAWM are so far poorly understood. It is suggested that free radical 
mediated mitochondrial injury may be an important factor driving progressive axonal 
dysfunction and loss in MS (Lassmann et al., 2007).  
Grey matter: MS lesion can also be located in the grey matter, especially in the 
cerebral cortex. Cortical lesions have been observed 80% of patients with PPMS. 
The histopathological characteristics of these cortical lesions differ substantially 
from white matter lesions (Calabrese et al., 2010). Three types of cortical lesions 
have been reported. Two of these lesions may appear in continuity with subcortical 
white matter plaques (type I) or as small intracortical perivascular lesions (type II). 
The most abundant form of cortical demyelination is subpial demyelination, which 
appears as large band-like lesions extending from the outer surface of the cortex into 
its deeper layer (type III) (Peterson et al., 2001).  
Although cortical lesions are characterized by substantial loss of oligodendrocytes 
and axons (Peterson et al., 2001; Albert et al., 2007), they differ markedly from white 
matter lesions in terms of the degree and type of inflammation. Pure intracortical 
lesions typically have a very low degree of inflammation (Peterson et al., 2001; Bo et 
al., 2003; Geurts et al., 2005; Kutzelnigg et al., 2005). Perivascular infiltrates are 
rarely found in the MS cortex, and the density of infiltrating lymphocytes in pure 
cortical lesions is similar to the density of infiltrating lymphocytes in normal 
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appearing grey matter. Therefore, in cortical lesions demyelination processes may 
not be solely immune-mediated. 
2.2 Immunopathogenesis of multiple sclerosis 
2.2.1 Activation of immune cells  
The cause of MS is still unknown and its pathogenetic pathways are not fully 
understood. Studies of experimental autoimmune encephalomyelitis (EAE), an 
animal model for MS, have indicated the role of myelin specific CD4+ Th1 and Th17 
as the driving force in the autoimmune processes, but other cell types that contribute 
to the pathogenesis of MS, such as CD8+, B cells, or NK cells have also been 
investigated (Batoulis et al., 2010). 
The initial step in immune cell activation is to activate dendritic cells (DC) via toll 
like receptors, which recognize very specific microbial products. After ligation, the 
DCs are activated and these cells start to produce type I IFNs. Once activated, CD4+ 
T cells interact with DC through the HLA class II molecule that recognizes the T-cell 
receptor (TCR) on the T cells (signal 1) in the secondary lymphoid organ (Figure 4 
and 5). However, activation of T cells also requires additional signals. Interaction 
with HLA and TCR induces activation of CD40 ligand (CD154) on the surface of T 
cells, which binds to it receptor CD40 on the DC. This interaction induces 
upregulation of CD80 (B7-1) and CD86 (B7-2) on the surface of DC that interacts 
with CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA4) on the surface of the T 
cells (Signal 2). CD28 is associated with the activation of T cells, whereas CTLA4 
(CD158) is more regulatory. After signal 2, DC start to produce important cytokines, 
which binds to receptors on the cell surface of T cells and drive them to secrete 
different cytokines. For example, secretion of IL-10, IL-12, IL-4 or combination of 
Interleukin (IL)-6/IL-1/IL-23 promotes differentiation to Th3, Th1, Th2, and Th17, 
respectively. (Kasper and Shoemaker, 2010) 
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Figure 4. Activation and differentiation of the naive CD4+ T cells. A. On 
activation, the dendritic cells (DC) interact with T-cell receptor (TCR) on 
the surface of the T cells (signal 1). This induces activation of CD40 ligand 
(CD154) on the surface of the T cell, which binds its receptor CD40 on the 
DC. Then, upregulation of CD80 and CD86 on the surface of the DCs are 
induced.  These molecules then interact with CD28 and cytotoxic T-
lymphocyte antigen-4(CTLA4) on the surface of the T cells (signal 2), 
which finally activates T cell and leads to secretion of cytokines by the DC. 
B. Naive CD4+ T cells differentiation depends on the cytokine mileu. 
Secretion of Interleukin (IL)-10, IL-4, IL-12 or a combination of IL-6 and IL-
23 promotes differentiation to T helper (Th) 3, Th2 and Th1 and Th17, 
respectively. Abbreviations: IFN interferon; MHC major histocompatibility 
complex; TGF transforming growth factor. Redrawn from Kasper and 
Shoemaker, 2010 and Fletcher et al., 2010. 
2.2.2 Transmigration of immune cells to the central nervous 
system 
Peripherally activated T cells enter distinct CNS microenvironments via the blood-
brain barrier (BBB) within the CNS parenchyma and by blood-CSF barrier (BCB) 
within choroid plexus (figure 5). Tight junctions between endothelial cells of the 
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BBB and the epithelial cells of the BCB limit immune cells access to the CNS 
(Holman et al., 2011). However, activated and memory T cells can transmigrate into 
the CNS, because they express adhesion molecules, chemokine receptors and 
integrins that enable these cells to readily cross these barriers (Engelhardt et al., 
1998; Engelhardt, 2008). The migration of leukocytes from blood into the CNS 
includes chronological leukocyte-endothelial interactions. Tethering and rolling of 
the leukocytes on the vascular endothelial surface initiate this process that is 
mediated by selectins and carbohydrate counter receptors. During the rolling, 
leukocytes also interact with the chemokines, which are produced on the endothelial 
surface. Chemokine stimulation induces upregulation of adhesion molecules of the 
integrin family on the leukocyte surface and leads to firm adhesion of leukocytes to 
the vascular endothelium by binding to cell adhesion molecules or the extracellular 
matrix component. This process ultimately leads to leukocyte transmigration to the 
CNS (Prendergast and Anderton, 2009). 
2.2.3 Mechanisms of neural tissue damage  
In the CNS, CD4+ T cells are reactivated and then mediate activation of 
macrophages/microglia, B cells and cytotoxic CD8+ T cells (Figure 5). Tissue 
damage in the inflammatory lesion of the brain and spinal cord may be induced by 
numerous mechanisms, such as cell-, cytokine, antibody- and radicals-mediated 
mechanisms (Lassmann, 2010).  
Macrophage/microglia-mediated damage: Activated macrophages and 
microglia have an important role in the CNS lesion development. They produce a 
large array of toxic molecules, such as proteo- and lipolytic enzymes, cytotoxic 
cytokines, excitotoxins and reactive oxygen species or nitric oxide (NO) 
intermediates, which are potential inducers of axonal damage. For axonal injury, 
oxygen and NO radicals seem to be of particular importance (Jack et al., 2005; van 
Horssen et al., 2011). 
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Figure 5. Current understanding of immunological evens in MS. 1) Autoreactive 
T cells are activated in secondary lymphoid tissue; 2) Activated T cells 
express adhesion molecules which enables them to transmigrate into the 
central nervous system (CNS); 3) Within the CNS, myelin specific T cells 
are reactivated and start to produce cytokines, like T helper (Th) 1 and 
Th17 cells produce tumor necrosis factor (TNF)-? and interferon (IFN)-?, 
which may damage oligodendrocytes and neurons. Th2 cells secrete anti-
inflammatory cytokines, which provide help to B cell-mediated tissue 
damage. Abbreviations: HLA human leukocyte antigen; LFA lymphocyte 
function associated antigen; VLA very late antigen; NK natural killer cells; 
Treg regulatory T cells; ICAM intracellular adhesion molecule: VCAM 
Vascular cell adhesion protein 1; IL interleukin. Picture adopted from the 
article by Holmoy and Hestvik, 2008, reproduced with permission of the 
publisher. 
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T cells are also central to MS lesion development. Both CD4+ and CD8+ T cells 
can express ligands for death receptors. Among them, TNF-related apoptosis 
inducing ligand (TRAIL), Fas ligand (FasL), tumor necrosis factor (TNF)-? have 
been described to mediate neuronal and oligodendrocytes damage (Aktas et al., 
2006). CD8+ T cells are more prevalent in the MS lesions than the CD4+ T cells, and 
CD8+ cells can recognize antigen presented on HLA class I on neurons and 
oligodendrocytes and kill the target cells (Hauser et al., 1986; Friese and Fugger, 
2009).  
B cells and antibodies, B cell derived plasma cells and antibodies are found in 
the CNS of MS patients (Baranzini et al., 1999). The target antigens of the humoral 
immune response in MS are still largely unknown, but it is suggested that the 
primary targets of the antibodies are the proteins of the myelin sheath, such as MBP, 
myelin oligodendrocytes glycoprotein (MOG) and proteolipid protein (PLP). 
Possible mechanisms are the antibody-mediated complement activation and 
antibody-dependent cellular cytotoxicity via Fc-receptors (Franciotta et al., 2008; 
Weber et al., 2011) 
Pathological analyses of actively demyelinating lesions have revealed four 
different structural and immunological features. Separate pattern of demyelination 
were homogenous in multiple lesions of the same patients, but different between the 
patients (Lucchinetti et al., 2000) (Figure 6). In these lesions, activated macrophages 
or microglia, cytotoxic cytokines, reactive oxygen and nitrogen species or specific 
demyelinating antibodies and activated complement component could be found. 
Although all actively demyelinating lesions were associated with an inflammatory 
infiltrates composed mainly of T lymphocytes and macrophages, they segregated into 
the four different patterns (Pattern I-IV) based on the distribution of myelin protein 
loss, the plaque geography and extension, pattern of oligodendrocyte destruction and 
the immunological evidence of immunoglobulins and activated complement deposit. 
Demyelination may be induced by macrophages and their toxic products (pattern I), 
by specific demyelinating antibodies and complement (pattern II), by degenerative 
changes in distal processes, in particular periaxonal oligodendrocytes followed by 
apoptosis (pattern III) or by primary degeneration of oligodendrocytes followed by 
myelin destruction (pattern IV). 
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Figure 6. Summary of pathogenetic mechanism of formation of actively 
demyelinating lesions. Blue spheres indicate normal myelin sheath and 
red spheres demyelinated myelin sheath. Inflammation: T helper (Th) 1 
cells maintain the inflammation in the central nervous system (CNS). 
These cells secrete proinflammatory cytokines that induce activation of 
macrophages (M), which are mainly responsible for the demyelination and 
axonal injury. Also Th2 and cytotoxic class I-restricted T cells (Tc1) might 
modify the outcome of the lesions. Demyelination: myelin sheath and 
oligodendrocytes (OG) are destroyed with multiple mechanisms. Four 
different mechanisms (pattern) in active demyelinating lesions have been 
found. Axonal injury: axonal injury follows acute destruction of myelin 
sheath. Abbreviations: C complement; GC galactocerebroside; M 
macrophages; MOG myelin oligodendrocytes glycoprotein; NO nitric 
oxide; ROI reactive oxygen species; TNF tumor necrosis factor; Y 
antibody. Redrawn from Lassmann et al., 2001.  
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2.2.4 Apoptosis  
Once T cells have been activated and the invading antigen has been eliminated, T 
cells must be eliminated to maintain homeostasis. Some of T cells develop into the 
memory T cells and these cells are resistant to death by apoptosis. T cell survival is 
dependent on the signals, which cells receive through the TCR and costimulatory 
molecules, such as CD28, adhesion molecules and cytokines and through pro- and 
anti-apoptotic molecules (Krammer et al., 2007). Apoptosis can be triggered by two 
mechanisms: activation-induced cell death (AICD) and activated T cell autonomous 
death (ACAD). In AICD, apoptosis is induced when activated T cells are 
restimulated via TCR in the absence of appropriate co-stimulation. Then apoptosis 
can be triggered by an intrinsic or an extrinsic mechanism. However, activated T-cell 
death by ACAD does not require restimulation of TCR, and it is mediated by the 
intrinsic pathway. ACAD is also known as death by neglect, death by cytokine 
withdrawal or passive cell death (Brenner and Mak, 2009). T-cell apoptosis may be 
induced by several mechanisms: by extrinsic cell-death-receptor and caspase-
dependent apoptosis, by intrinsic mitochondria- and caspase-dependent apoptosis, or 
by caspase-independent cell death. (Krammer et al., 2007) 
In MS, a failure in the apoptosis cell death of autoreactive T cells is an important 
pathophysiological mechanism. Apoptosis is an important mechanism in immune 
system regulation in relation to the elimination of autoreactive T and B cells and 
macrophages from the circulation preventing their entry into the CNS (Pender, 
2007). In EAE, T-cell apoptosis occurs in the CNS in acute EAE and plays an 
important role in the spontaneous recovery from disease. The main site of T-cell 
apoptosis is the brain parenchyma rather than perivascular space or meninges 
(Pender et al., 1991; Schmied et al., 1993; Tabi et al., 1994; Bauer et al., 1998). 
The intrinsic apoptotic pathway is regulated by the balance between 
proapoptotic and antiapoptotic members of the B-cell lymphoma 2 (BCL-2) family, 
and it crucially depends on permeabilization of the outer mitochondrial membrane 
(Figure 7B). This pathway can be triggered by several stimuli, including TCR 
stimulation, UV-irradiation, DNA damage, endoplasmic reticulum stress, hormones 
and cytokine deprivation. Mitochondrial membrane permeabilization results in the 
release of mitochondrial content, including molecules such as cytochrome c. Release 
of cytochrome c induce formation of apoptosome that leads to activation of initiator 
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caspase-9, which then activates downstream effector caspases (Krammer et al., 
2007). 
BCL-2 family members have both pro- and antiapoptotic functions, and these 
proteins are divided into three subgroup based on their structure (Table 2). All of 
these proteins contain between one to four distinct regions of homology, which are 
known as BH domains (Cepok et al., 2009). Antiapoptotic BCL-2 proteins contain 
four BH domains (BH1-4) and are generally integrated mostly within the outer 
mitochondria membrane. BCL-2, A1, BCL-XL and MCL-1 are the most important 
members of anti-apoptotic BCL-2 family and their function is to inhibit proapoptotic 
BCL-2 protein from permeabilization of the outer mitochondria membrane and 
release cytochrome c. (Sattler et al., 1997; Chipuk et al., 2010)  
Table 2. BCL-2 family members 
Class Members Structure 
Anti-apoptotic BCL-2 family proteins A1, BCL-2, BCL-XL, MCL-1 BH1-BH4 
Pro-apoptotic effector proteins BAX, BAK, BOK BH1-BH3 
Pro-apoptotic BH3-only proteins BID, BIM, BAD, BIK, BMF, HRK, NOXA, PUMA BH3 
Abbreviations: BCL B-cell lymphoma; MCL-1 Induced myeloid leukemia cell differentiation 
protein; BAX Bcl-2–associated X protein; BAK Bcl-2 homologous antagonist/killer; BOK Bcl-
2-related ovarian killer protein; BID BH3 interacting domain death agonist; BIM Bcl2-
interacting mediator of cell death; BAD BCL2-associated agonist of cell death; BIK BCL2-
interacting killer (apoptosis-inducing); BMF Bcl2 modifying factor; HRK harakiri, BCL2 
interacting protein (contains only BH3 domain); NOXA Phorbol-12-myristate-13-acetate-
induced protein-1;  PUMA p53 up-regulated modulator of apoptosis.  
 
BCL-2 proapoptotic members are divided into the effector proteins and BH3-only 
proteins. The effector proteins BAK and BAX homo-oligomerize into proteolipid 
pores within the outer mitochondria membrane and induce outer mitochondria 
membrane permeabilization (Mikhailov et al., 2003). BH3-only proteins function is 
to interact with the antiapoptotic BCL-2 family members and trigger apoptosis when 
overexpressed. BIM and PUMA can bind antiapoptotic BCL-2 and BCL-XL, which 
induces inhibition of BAK and BAX and results in cytochrome c release and 
induction of cell death (Bouillet and Strasser, 2002). Therefore, the ratios of 
antiapoptotic to proapoptotic BCL-2 family members determine whether cells die or 
live (Chipuk et al., 2010). 
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Figure 7. Apoptosis can be triggered by two main pathways. A) The extrinsic 
pathway is mediated death factors, like Fas ligand (FasL), tumor necrosis 
factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL).  These 
death factors induce the apoptosis signal cascade via death inducing 
complex (DISC). B) Mitochondrial damage, due to anticancer drugs, ?-
radiation, antioxidants, growth factor or serum deprivation, leads to 
cytocrome c release from mitochondria into to the cytosol. Cytocrome c 
can activate caspase 9 together with adaptor apoptotic protease activating 
factor 1 (Apaf-1) and thus activates effector caspases. This pathway is 
also called the intrinsic pathway.  Picture adopted from the article by 
Krammer et al., 2007, reproduced with permission of the publisher. 
In the extrinsic apoptotic pathway, proapoptotic signals are triggered by signals 
emanating from the cell-surface death receptors (DR) that are activated by ligands, 
such as TNF, FasL and TRAIL (Figure 7A). DRs are defined by the presence of a 
death domain (DD), which is essential for the apoptosis induction (MacEwan, 2002).  
The transduction of the apoptotic signals from the cell death receptors starts with 
the formation of a large protein complex at the cell membrane, known as the death-
inducing signaling complex (DISC), in which activation of caspase-8 and caspase-10 
takes place. Activated caspases-8 and caspase-10 directly lead to the activation of 
downstream effector caspases caspase-3, caspase-6 and caspase-7 that lead to cell 
death. Sometimes formation of DR-DISC is reduced leading to lower levels of active 
caspase-8. In these cases apoptosis is induced by cleavage of BCL-2 family protein 
BID, which interacts with BAX or BAK. This interaction induces the release of 
cytochrome c from mitochondria that results in the formation of a multi-protein 
complex apoptosome, which can lead to the activation of caspase 9, and then 
downstream downstream effector caspases (Krammer et al., 2007). 
2.3 Cytokines and chemokines 
2.3.1 Cytokines 
Cytokines are soluble proteins or glycoproteins that mediate the pathogenesis of MS. 
Constitutive production of cytokines is usually low or even absent and they are 
generally produced in small quantities in response to local stimulus, such as the 
presence of antigen or endotoxin, or the transduction of signal provided by other 
cytokines (Ozenci et al., 2002). 
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It is generally known that IFN-?, TNF-? and IL-6 play an important role in MS 
pathogenesis (Table 3). Elevated levels of IFN-? have been detected in the CNS at 
the peak of EAE disease and treatment of patients with IFN-? was deleterious to MS 
patients (Panitch et al., 1987). Also elevated levels of TNF-? have been detected 
within MS lesions (Hofman et al., 1989). TNF-? is also present in higher amount in 
the serum and CSF of MS patients compared to healthy controls and it also correlates 
with the severity of the lesions and disease progression (Maimone et al., 1991; 
Sharief and Hentges, 1991). IL-6 has been detected in chronic MS lesions and IL-6 
deficient mice were resistant to EAE (Okuda et al., 1999; Okuda et al., 2000). 
Previously, IL-6 was believed to mediate the generation of Th1 cells and therefore 
modulate the Th1/Th2 balance. Recently, IL-6 together with IL-23 have been shown 
to be essential factors required for the expansion of a pathogenic CD4+ T cell 
population to IL-17 producing Th17 cells (Lovett-Racke et al., 2011). Until now, the 
IL-23/Th17 pathway has been  thought play an important role in MS. IL-17 is 
elevated in the active MS brain lesions (Lock et al., 2002; Tzartos et al., 2008). Th17 
cells have shown to migrate efficiently through a model of the BBB, accumulate in 
MS lesions and secrete granzyme B and other cytolytic enzymes that kill neurons 
(Kebir et al., 2007). A higher number of IL-17 positive mononuclear cells in blood 
and CSF were detected compared to healthy controls. Increased levels of IL-17 have 
been found in mononuclear cells in MS patients during exacerbation and it decreased 
in response to high dose of IFN-? and GA (Durelli et al., 2009).  
Similarly to TNF-?, other cytokines of the TNF ligand superfamily participate in 
immune cell activation and differentiation, as well as maintaining the homeostasis of 
the immune system via apoptosis. The best characterized of these ligands are TNF-?, 
FasL and TRAIL. They are membranous proteins that are also cleaved from the cell 
membrane by the metalloproteinases (Tanaka et al., 1998; Bossi and Griffiths, 1999; 
Croft, 2009).  
Fas/FasL interaction is essential for T-cell homeostasis by deletion of autoreactive 
T cells. Membranous FasL primarily mediates apoptosis and soluble FasL can have a 
both pro- and antiapoptotic functions depending on the nature of the other 
appropriate mediators in the microenvironment. The antiapoptotic function is 
mediated by sFasL that competes with the membranous form of Fas binding. 
Sometimes sFasL can interact with extracellular matrix proteins that may potentiate 
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its proapoptotic activity (Aoki et al., 2001). In contrast to FasL, the soluble form of 
the Fas receptor is generated by alternative splicing of mRNA instead of proteolytic 
cleavage of membranous protein (Cascino et al., 1995). sFas have a negative 
regulatory effect on the membrane-bound Fas, because both forms can bind to FasL 
(Cheng et al., 1994).  
In MS, several studies have detected upregulated levels of Fas and FasL in MS 
lesions indicating these molecules to be potential effectors of this disease (D'Souza et 
al., 1996; Dowling et al., 1996; Bonetti and Raine, 1997). Elevated Fas expression on 
oligodendrocytes in chronic active and chronic silent MS lesions compared to 
oligodendrocytes in control tissue from subjects with or without other neurological 
diseases has been found (D'Souza et al., 1996; Bonetti and Raine, 1997). FasL 
expression is localized to microglia cells and T cells. In vitro, FasL was shown to 
induce cell death of oligodendrocytes (D'Souza et al., 1996). Defective T cell Fas 
function in patients with MS has also been reported (Comi et al., 2000). This is also 
supported by studies that have reported upregulated level of sFas in sera and CSF of 
patients with RRMS patients, especially during clinical disease activity (Inoue et al., 
1997; Zipp et al., 1998b; Boylan et al., 2001). Moreover, intrathecal production of 
sFas has been reported in MS (Ciusani et al., 1998). Furthermore, it was confirmed 
that sFas is biologically active via inhibition of FasL-mediated apoptosis in MS 
(Zipp et al., 1998a). 
TRAIL (Apo2L, TNFRSF10) is abundantly expressed in immune cells, especially 
in the NK cells, NKT cells and macrophages.  Also the soluble trimeric form is 
biologically active (Bodmer et al., 2000; Trabzuni et al., 2000). TRAIL is considered 
to play a crucial role in maintaining T-cell homeostasis, as well as killing tumor and 
virally transformed cells by NK and NKT cells. TRAIL is present at high levels in 
chronic and acute MS lesions, where the most relevant sources include activated 
microglia and invading immune cells (Cannella et al., 2007).  
In EAE models, TRAIL has been shown to inhibit disease development (Hilliard 
et al., 2001; Cretney et al., 2005). In vitro studies have shown that recombinant 
TRAIL inhibits T-cell activation and proliferation, but does not induce apoptosis in 
the T cells (Song et al., 2000; Lunemann et al., 2002). In the CNS, TRAIL has been 
shown to mediate apoptosis of human neurons and oligodendrocytes (Nitsch et al., 
2000; Matysiak et al., 2002). In the EAE model, intracerebral injection of soluble 
38 
TRAIL was shown to increase neuronal apoptosis and increase clinical deficits 
(Aktas et al., 2005).  
Table 3. Cytokines described in MS 
Ligand Receptor Produced 
by 
Function in MS Ref. 
Predominantly proinflammatory  
IFN-? IFNGR1- 
IFNGR2 
NK,  
??T 
CD8+ 
Th1 CD4+ 
-Activates mononuclear cells, induces MHC I 
and MHC II expression, influences antibody 
production and apoptosis of T cells 
-Detected in the MS lesions and increased 
levels of IFN-? are associated with disease 
exacerbation  
 
1,2 
TNF-? TNFR1, 
TNFR2 
??, 
microglia 
astrocytes 
T cells 
-Activates mononuclear cells, induces 
expression of adhesion molecules, 
chemokines and cytokines and triggers 
apoptosis of oligodendrocytes  
-Expressed in the active MS lesions and 
increased levels are associated with active 
disease  
 
1,3,4 
IL-17 IL17R,  
IL17R? 
Th17 
CD8+ 
NK  
NKT 
-Induces secretion of proinflammatory 
cytokines and chemokines, activate microglia 
cells and mediate BBB disruption  
 -Elevated in active MS brain lesions and 
increased levels associated with active 
disease  
 
5,  
6-8 
IL-6 IL6R?-
gp130 
T cells  
?? 
-Induces differentiation of Th17 cells and B 
cell differentiation and immunolglobulin 
production  
-Detected in MS lesions, but no association 
with disease activity or progression  
 
1,  
3-9 
IL-23 IL23R-
IL12R?1 
??  
DC 
-Efficient role in differentiation and survival of 
Th17 cells  
-Increased levels in RRMS patients  
 
5, 10 
IL-12 IL12R?1-
IL12R?2 
Monocytes 
DC 
-Mediates differentiation of Th1 cells  
-Elevated in the acute MS lesions, increased 
in the RRMS and SPMS patients and 
correlate with development of active MS 
lesion  
 
10-
13 
FasL FAS Microglia 
T cells 
NK 
-Mediates apoptosis of immune cells and 
oligodendrocytes  
-Detected in MS lesions and increased 
levels of sFas were detected in some studies  
 
14-
17 
TRAIL TRAILR1,  
TRAILR2, 
DcR1, 
DcR2,  
OPG 
NK 
NKT 
?? 
-Inhibits T-cell activation and mediate 
apoptosis of neurons and oligodendrocytes  
-Expressed in the MS lesions and suggested 
as potential response marker for IFN-? 
therapy  
18, 
19 
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Predominantly regulatory  
IL-4 IL4R?-
IL4R? 
Th2 -Mediates differentiation of Th2 cells and B 
cells  
-Detected MS lesions and increased levels 
detected during the relapse 
 
1, 
20, 
21 
IL-10 IL-10R?-
IL10R? 
Monocytes 
?? 
B cells 
Th2  
-Inhibits production of proinflammatory 
cytokines and T-cell proliferation  
-Decreased levels of IL-10 detected before 
exacerbation  
 
1, 22 
TGF-? TGFBR1-
TGFBR2 
Treg 
Monocytes 
Astocytes 
Microglia 
-Inhibits proliferation of T cells and 
macrophages, maturation of cytotoxic 
lymphocytes and NK cells 
-Decreased levels of TGF-? in blood 
detected in RRMS patients  
1, 22 
Abbreviations: IFN interferon; TNF tumor necrosis factor; IL interleukin; FasL Fas ligand; 
TRAIL TNF-related apoptosis inducing ligand; TGF transforming growth factor; R receptor; 
Dc decoy; OPG osteoprotegrin; M? macrophages; NK natural killer cells; NKT natural killer 
T cells; Th T helper cells; Treg regulatory T cells. 
1) Imitola et al., 2005; 2) Traugott and Lebon, 1988; Hohnoki et al., 1998); 3) Cannella and 
Raine, 1995; 4) Spuler et al., 1996; 5) Jadidi-Niaragh and Mirshafiey, 2011;  
6) Durelli et al., 2009; 7) Tzartos et al., 2008; 8) Lock et al., 2002; 9) Harris and Sadiq, 
2009a; 10) Alexander et al., 2010; 11) Fletcher et al., 2010; 12) van Boxel-Dezaire et al., 
1999; 13) van Boxel-Dezaire et al., 2001; 14) D'Souza et al., 1996;  
15) Aktas et al., 2006; 16) Dowling et al., 1996; 17) Bonetti and Raine, 1997;18) Hoffmann et 
al., 2009; 19) Wandinger et al., 2003; 20) Bartosik-Psujek and Stelmasiak, 2005a; 21) 
Cannella and Raine, 1995; 22) Rieckmann et al., 1994. 
 
2.3.2 Chemokines  
Chemokines and their receptors play an important role of the recruitment of immune 
cells from the periphery into the CNS (Savarin-Vuaillat and Ransohoff, 2007). The 
chemokine family comprises approximately 50 ligands and 20 receptors in humans. 
Chemokines are small soluble (8-14 kDa) proteins that are classified into four main 
families based on the location of intramolecular disulphide bonds (CC, CXC, CX3C, 
CX) in the N-terminus. Chemokines bind to their corresponding seven-
transmembranedomain G-protein coupled receptor on the target cells.  Most of the 
chemokine receptors and ligand do not have specific pairs, but for instance ten 
different CC family ligands can bind to chemokine receptor CCR1. Conversely, 
some ligands can productively signal many receptors, such as CCL3 can signal with 
CCR5 and CCR1.(Moser et al., 2004) 
In the MS pathogenesis several chemokines and chemokines receptors have been 
shown to be important (Table 4). For example, CCL2, CCL4, CCL5, CXCL10, 
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CXCL12, and CXCL13 and their receptors including CCR1, CCR2, CCR5, CXCR3, 
and CXCR4 have been detected in the active MS lesions, as well as in CSF and 
blood where they were considered to reflect disease activity (Szczucinski and Losy, 
2007). Recently, expression of CXCR3+ on circulating CD8+ cells was associated 
with MRI measurements of inflammatory activity and tissue destruction (Fox et al., 
2008). Interestingly, it has been reported that IFN-? can modulate the levels of 
several chemokines (CCL1, CCL2, CCL7, CXCL10 and CXCL11) in blood and 
CSF, thus limiting the entry of immune cells into the CNS (Cepok et al., 2009; 
Sellebjerg et al., 2009b).  
Table 4. Chemokines described in MS 
Chemokine Chemokine 
receptors 
Target 
cells 
Role in MS Ref. 
CCL2 
(MCP-1) 
CCR2 Monocytes 
T cells 
NK  
- Detected in the MS lesions by 
astrocytes and macrophages  
- Decreased expression of CCL2 in 
the CSF and blood of MS patients, 
especially during active disease  
 
1-6 
CCL3 
(MIP-1?) 
CCR1 
CCR5 
Monocytes - Detected in actively demyelinating 
lesions by macrophages and 
microglia  
- Increased expression of CCL3 in 
the CSF during active disease 
 
2,7 
CCL4 
(MIP-1?) 
CCR5 Th1 
Monocytes 
- Detected in actively demyelinating 
lesions by macrophages and 
microglia  
- Not known in MS 
 
2 
CCL5 
(RANTES) 
CCR1 
CCR5 
Monocytes 
Th1 
- Detected in actively demyelinating 
lesions by macrophages and 
microglia  
- Increased expression of CCL5 in 
the CSF and blood of MS patients , 
especially during active disease  
 
2,8-10 
CCL7 
(MCP-3) 
CCR1 
CCR2  
Monocytes - Detected in the acute and chronic 
MS lesions by astrocytes and 
inflammatory cells  
- Studies of CCL5 in blood or CSF 
not available  
 
1 
CCL8 
(MCP-2) 
CCR3 Monocytes 
 T cells 
- Detected in the acute and chronic 
MS lesions by astrocytes and 
inflammatory cells  
- Studies of CCL8 in blood or CSF 
not available 
 
1 
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CXCL8 
(IL-8) 
CXCR1 
CXCR2 
Monocytes - Detected in active MS lesions by 
astrocytes  
- Increased secretion of CXCL8 in 
blood of MS patients  
 
11-13 
CXCL9 
(MIG) 
CXCR3 Th1  - Detected in actively demyelinating 
lesions by astrocytes and 
macrophages  
- Increased secretion of CXCL9 in 
CSF from active MS patients 
 
10,14 
CXCL10  
(IP-10) 
CXCR3 Th1 - Detected in actively demyelinating 
lesions by astrocytes (Simpson et 
al., 2000)  
- Decreased expression of CXCL10 
in the CSF and blood of MS 
patients, especially during active 
disease  
 
3-6, 15 
CXCL12  
(SDF-1) 
CXCR4 
CXCR7 
Lympho-
cytes 
MC 
- Detected in active and chronic 
inactive lesions by astrocytes  
- CXCL12 were expressed 
constitutively in blood and CSF in 
MS 
 
16,17 
CXCL13 
(BCA-1) 
CXCR1 B cells - Detectable in the active MS lesions 
by perivascular infiltrates  
- Increased secretion of CXCL13  in 
the CSF and blood of active MS 
patients  
 
16-18 
Abbreviations: CCL C-C motif chemokine ligand; CXCL C-X-C motif chemokine ligand; 
CCR C-C motif chemokine receptor; CXCR C-X-C motif chemokine receptor; NK natural 
killer cells; Th T helper cells.  
1) McManus et al., 1998; 2) Simpson et al., 1998; 3) Franciotta et al., 2001; 4)Scarpini et al., 
2002; 5) Sorensen et al., 2001; 6) Mahad et al., 2002; 7)Miyagishi et al., 1995; 8) Bartosik-
Psujek and Stelmasiak, 2005a; 9) Sindern et al., 2001; 10) Sorensen et al., 1999; 11) Omari 
et al., 2005; 12) Lund et al., 2004; 13) Bartosik-Psujek and Stelmasiak, 2005b; 14) Simpson 
et al., 2000 ; 15) Balashov et al., 1999; 16) Krumbholz et al., 2006; 17) Sellebjerg et al., 
2009a; 18) Festa et al., 2009. 
3. Biomarkers in multiple sclerosis  
Biomarkers are measurable indicators of normal biological and pathogenic processes, 
or pharmacological responses to a therapeutic intervention. A good biomarker should 
be precise and reliable, distinguishable between normal and MS disease. 
Measurements of biomarkers are traditionally limited to detection of specific proteins 
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in the body fluids (blood, CSF, urine) that become altered as a consequence of a 
biologic or pathologic process (Biomarkers Definitions Working Group., 2001; 
Bielekova and Martin, 2004). 
Most MS lesions are typically located in the periventicular white matter of the 
brain as well as superficial areas of the spinal cord, which share a close anatomical 
relationship with CSF space (Tumani et al., 2009). Because brain biopsies are mostly 
unavailable, CSF is important sample in understanding the pathology of MS. CSF 
can be used for measurements of various soluble markers and cell populations by 
flow cytometry analysis, PCR studies and cell functional studies. However, CSF 
collection is an invasive procedure, and therefore it is collected only rarely, usually 
during the diagnostic procedure. (Bielekova and Martin, 2004) 
Biomarkers that are measurable from the peripheral blood are of great clinical 
value because of the non-invasive collection method. The main disadvantage of 
blood is that the disease pathology is restricted to the CNS that is separated from the 
periphery by the BBB. Therefore, biological events that are associated with CNS 
lesions may not be measurable in the peripheral blood. Also, the diurnal variation of 
many soluble markers and levels of measured markers are often affected by systemic 
infections, by biological degradation in the liver or by excretion in the kidney. 
However, peripheral blood biomarkers can provide important information regarding 
immune triggers of MS, as well as the therapeutic efficacy of drugs administered 
systemically. (Bielekova and Martin, 2004; Harris and Sadiq, 2009b; Tumani et al., 
2009) It is also noteworthy that the majority of protein content of the lumbar CSF is 
blood-derived and the remainder consists of less brain-derived or intrathecally 
produced proteins. Under physiological conditions blood-derived proteins enter into 
the CSF compartment via passive diffusion across the blood-CSF barrier (Tumani et 
al., 2009). 
Pathological studies have revealed several mechanisms that are important in MS 
pathogenesis and therefore classification of process-specific biomarkers is based on 
these studies (Trapp et al., 1998; Lucchinetti et al., 2000). Thus, biomarkers can be 
categorized into the following classes:  inflammation, BBB function, degeneration 
and regeneration (Table 5) (Bielekova and Martin, 2004). 
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3.1 Biomarkers of inflammation  
Cytokines and cytokine receptors. Many cytokines and their receptors have 
been detected in the MS lesions and they are thought to play a role in the MS 
pathogenesis via immune system activation as well as via damaging neuronal cells. 
Proinflammatory cytokines have been studied extensively. CSF levels of 
proinflammatory cytokines are often elevated in MS patients (Rieckmann et al., 
1994; Spuler et al., 1996; Fassbender et al., 1998; van Boxel-Dezaire et al., 2001; 
Bartosik-Psujek and Stelmasiak, 2005a; Malmestrom et al., 2006; Tzartos et al., 
2008).Some studies have reported an association between increased cytokine levels 
in the CSF with the clinical disease activity and Gd-enhancing lesions in the MRI 
scan, but others could not confirm these findings (Spuler et al., 1996; Giovannoni et 
al., 2001).  
Chemokines and chemokine receptors. Chemokines and their receptors play an 
important role in the recruitment of immune cells from the periphery to CNS and 
they have been detected in MS lesions (Szczucinski and Losy, 2007). CXCL13 has 
been shown to be upregulated in  active MS patients and elevated levels might 
predict CIS conversion to CDMS (Festa et al., 2009; Sellebjerg et al., 2009a; 
Brettschneider et al., 2010; Khademi et al., 2011; Ragheb et al., 2011) 
Antibodies. Intrathecal immunoglobulin synthesis and the presence of OCB in 
MS patients has been most the important and earliest evidence suggesting a role for 
B cells and antibodies in the pathology of MS (Awad et al., 2010). The presence of 
anti-myelin antibodies has been suggested to be a valuable marker for prognosis and 
progression in MS. The presence of serum IgM anti-MOG and anti-MBP antibodies 
has been shown to predict the risk of conversion from CIS to clinically definite MS 
in one study (Berger et al., 2003). Neuron-specific proteins are thought be important 
markers for MS. Anti-Neurofilament (NF) antibodies have been suggested to be 
markers of tissue damage in MS.  Anti-NF antibodies are detected both in serum and 
CSF of MS patients and they are shown to correlate with brain parenchymal fraction, 
T2 and T2 lesion load, and MRI marker of tissue damage (Silber and Sharief, 1999; 
Eikelenboom et al., 2003). In another study serum anti-NF antibodies were 
significantly elevated in PPMS (Ehling et al., 2004). 
Apoptosis-related molecules. Several studies have shown downregulation of pro-
apoptotic molecules in active MS indicating abnormalities in the apoptotic cell death 
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of lymphocytes in MS (Sharief, 2000b; Semra et al., 2001; Sharief et al., 2002). 
Increased mRNA expression of Fas and FasL have been consistently reported in the 
peripheral blood mononuclear cells (PBMC) in RRMS, but the data on the sFas in 
sera is contradictory(Inoue et al., 1997; Zipp et al., 1998b; Huang et al., 2000; 
Bilinska et al., 2003; Gomes et al., 2003; Mahovic et al., 2004). Upregulated 
expression of TRAIL mRNA has been reported in PBMC of IFN-? treated RRMS 
patients who respond to treatment.  Based on these observations it has been 
suggested that TRAIL could be used as a biomarker reflective of response to IFN-? 
treatment in MS. (Wandinger et al., 2003). 
3.2 Biomarkers of blood-brain barrier function 
Adhesion molecules. Transmigration of immune cells into the CNS is associated 
with BBB disruption and consecutive transendothelial migration of leukocytes that is 
mediated by adhesion molecules (Holman et al., 2011). Adhesion molecules are 
normally expressed at very low levels on vascular endothelial cells of normal brains, 
but the expression is upregulated after cytokine stimulation.  Adhesion molecules 
also exist in soluble forms, released from the endothelial cells, immune cells and 
platelets. Soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin have 
been shown to be upregulated in RRMS patients when compared to PPMS and the 
levels of these molecules are also upregulated during relapse suggesting that these 
molecules might be used as a biomarker for disease activity (Kuenz et al., 2005).  
Matrix metalloproteinases. MMPs are an important contributor to the 
inflammatory damage to BBB and myelin. Elevated level of MMP-9 correlated with 
Gd-enhancing lesions on MRI (Lee et al., 1999; Waubant et al., 2003). 
3.3 Biomarkers of degeneration  
Axonal and neuronal damage. Neurodegenerative biomarkers typically consist of 
neuron-specific proteins, which are released following axonal degeneration. Several 
studies have shown elevated CSF levels of NF in MS (Lycke et al., 1998; 
Malmestrom et al., 2003; Rejdak et al., 2008). Tau, protein of the axons, was found 
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to be upregulated in both RRMS and PPMS patients (Kapaki et al., 2000; Bartosik-
Psujek and Archelos, 2004; Martinez-Yelamos et al., 2004; Bartosik-Psujek and 
Stelmasiak, 2006; Guimaraes et al., 2006; Terzi et al., 2007). Furthermore, CSF 
levels of Tau tended to be highest in the early stage of the disease (Martinez-
Yelamos et al., 2004; Brettschneider et al., 2005). 
Oxidative stress and exicitoxicity. Oxidative stress may responsible for CNS 
degenerative events. NO is a free radical with multiple biological effects, such as 
oligodendrocyte injury, axonal degeneration, and impairment of nerve conduction 
(Lassmann, 2010). Elevated levels of NO have been detected in acute demyelinating 
lesions. Elevated levels of NO metabolites nitrite and nitrate are associated with 
disease activity (Yamashita et al., 1997; Brundin et al., 1999; Svenningsson et al., 
1999; Acar et al., 2003; Rejdak et al., 2004). NO synthase (NOS) was also increased 
in MS patients (Calabrese et al., 2002). 
3.4 Biomarkers of regeneration 
The expression of several neurotrophins has been observed in the MS lesions which 
can stimulate regeneration and promote repair. Neurotrophic factors are released 
mainly by T cells and other cells of the immune system.(Hohlfeld, 2008) 
Regeneration biomarkers have not been studied extensively. In MS patients, reduced 
levels of brain-derived neurotrophic factor (BDNF) have been reported in blood and 
CSF (Azoulay et al., 2005; Frota et al., 2009). The levels of BDNF, neural cell 
adhesion molecule (NCAM) and ciliary neurotrophic factor (CNTF) in the CSF of 
MS patients are associated with disease activity (Weinstock-Guttman et al., 2007; 
Frota et al., 2009).  
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Table 5. Summary of biomarkers in the multiple sclerosis. Modified from 
the Bielekova and Martin, 2004. 
Biomarker Predominant origin Description Usefulness in MS 
INFLAMMATION    
Cytokines   
Osteopontin Macrophages 
 
Mediate pro- and anti-
inflammatory activity in the 
CNS. Proinflammatory 
cytokines significantly 
associated with disease 
activity. 
Biomarkers of 
inflammatory 
disease activity. 
Not specific for 
MS. 
TNF-? CD4+ T cells 
  
MIF Macrophages 
T cells 
 
IL-17 Th17 cells 
 
IL-4 Th2 
 
IL-6 Th2 
 
IL-10 Th2 
Treg 
 
Chemokines and their receptors   
CXCL13 T cells,  
DC 
 
Mediate immune cell 
recruitment into the CNS. 
Biomarkers of 
inflammatory 
disease activity. 
Not specific for 
MS. 
CXCL10 Monocytes 
Endothelial cells 
 
CCL2 Astrocytes 
Glial cells 
 
Antibodies and complement   
Anti-MOG B cells 
 Reflect B cell mediated 
responses towards neuronal 
proteins 
Biomarkers of 
disease activity 
and disability 
Anti-MBP B cells 
 
Anti-NF B cells 
Apoptosis-related molecules   
Fas T cells 
Oligodendrocytes 
 
Mediate apoptotic events in 
immune and neuronal cells. 
Biomarkers of 
inflammatory 
activity and 
disability 
progression 
FasL T cells 
 
TRAIL T cells 
NK cells 
 
FLIP All 
BIRC All 
Bcl-2 All 
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BBB FUNCTION    
Adhesion molecules   
sICAM Endothelial 
cells 
Regulate immune cell 
transmigration into the CNS 
Biomarker for 
disease activity 
sVCAM Endothelial 
cells 
sP-selectin Endothelial 
cells 
sE-selectin Endothelial 
cells 
Matrix metalloproteinases   
MMP-2 M? 
T cells Mediate BBB disruption and may be also responsible of 
degenerative events 
Biomarkers of 
disease activity MMP-9 M? 
T cells 
DEGENERATION   
Axonal and neuronal damage 
   
Neurofilament Neuronal 
 
Represent degenerative 
phenomena in MS 
Biomarkers for 
disability 
Tau Neuronal 
 
14-3-3 Neuronal 
 
MBP Neuronal 
Oxidative stress and 
excitoxicity   
NO Macrophages 
Mast cells 
Astrocytes 
 
  
NOS Macrophages 
Mast cells 
 
Represent degenerative 
phenomena in MS 
Biomarkers for 
disease activity 
and disability 
Nitrate Macrophages 
Mast cells 
 
Nitrite Macrophages 
Mast cells 
REGENERATION   
NCAM Immune cells 
 
Neurotrophic factors in 
inflammatory lesions, which can 
stimulate regeneration and 
promote repair in the MS lesions 
Disability 
markers 
CNTF Immune cells 
 
BDNF Immune cells 
 
NGF Immune cells 
 
NT-3 Immune cells 
Abbreviations: TNF tumor necrosis factor; MIF macrophage migration inhibitory factor; IL 
interleukin; CXCL CXC motif chemokine; MOG myelin oligodendrocytes glycoprotein; MBP 
myelin basic protein; NF neurofilament; TRAIL TNF-related apoptosis inducing ligand; FLIP 
FLICE-like inhibitory protein; BIRC baculoviral IAP repeat-containing; Bcl-2  B-cell lymphoma 
2; ICAM Inter-cellular adhesion molecule; VCAM Vascular cell adhesion protein; MMP matrix 
metalloproteinase; NO nitric oxide; NOS NO synthetase; NCAM Neural cell adhesion 
molecule; CNTF ciliary neurotrophic factor; BDNF brain-derived neurotrophic factor; NGF 
nerve growth factor; NT-3 Neurotrophin-3; Th T helper cell; Treg Regulatory T cell; DC 
dendritic cell. 
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3.5 Magnetic resonance imaging as a surrogate 
marker for multiple sclerosis 
MRI is an important tool in evaluating MS patients and it is by far the most 
extensively measured biomarker in MS. It has a high sensitivity for detecting focal 
abnormalities in the CNS. The changes seen by MRI in MS patients reflect 
underlying pathology: inflammation and axonal degeneration (Katz et al., 1993; 
Bruck et al., 1997). Typical magnetic resonance sequences include T1-weighted with 
or without Gadolinium (Gd) administration, T2 weighted, proton-density, and fluid-
attenuated inversion recovery (FLAIR).  The inflammatory disease process in MS is 
thought to be reflected by the detection of Gd-contrast enhancing T1 lesions and new 
T2 white matter lesions and the axonal loss by T1 hypointense lesions. Gd-enhanced 
T1-weighted images reflect increased BBB permeability associated with acute 
inflammatory activity of MS (Kermode et al., 1988; McFarland et al., 2002; 
Tomassini and Palace, 2009). 
95% of patients with clinically definite MS have white matter lesion seen on brain 
MRI and their presence in patients with CIS is the strongest predictor of MS. The 
number and volumes of lesions correlated only weakly with future disability. 
Moreover, a determination of brain volumes has allowed an indirect quantification of 
cerebral tissue loss (brain atrophy) in MS patients and has been to shown to correlate 
with the disability. (Brex et al., 2002; McFarland et al., 2002) 
In addition to conventional MRI (dual-echo, FLAIR, and T1-weighted imaging 
with and without Gd administration), newer MRI techniques, like diffusion tensor 
imaging (DTI) may add new information on aspects of the pathomechanism. These 
techniques have the great advantage of being more specific towards the 
heterogeneous pathological substrates of the disease than conventional MRI. In 
addition, they also allow quantifying and monitoring the extent of damage not only 
in lesions but also in normal-appearing white matter and grey matter. Finally, the 
development of new analysis approaches to assess functional MRI (fMRI) data is 
disclosing, at an unprecedented pace, the mechanisms of cortical reorganization 
following the accrual of tissue damage, which have the potential to limit its clinical 
consequences (Filippi and Agosta, 2010). 
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AIMS OF THE STUDY 
MS is characterized by a variable clinical course and a heterogeneous and complex 
pathology and pathogenesis. Identification of immunological subtypes of MS in 
individual patients is an important issue. That will allow more focused application of 
different therapies in the management of MS. The goal of this thesis was to identify 
biomarkers in the blood that could reflect pathogenetic processes in MS and be used 
as biomarkers of disease activity and progression.  
 
Our specific aims were to:  
1) Define immune profiles in different clinical subtypes of MS and CIS 
2) Search for biomarkers for disease activity and disability  
3) Search for prognostic biomarkers for conversion of CIS to MS 
4) Explore whether the postpartum disease activation of MS is related to 
changes in the apoptotic molecules in blood. 
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SUBJECTS AND METHODS  
1. Subjects and ethical considerations (Studies I-IV) 
The study included 232 subjects: 93 RRMS, 29 SPMS, 21 PPMS 18 CIS and 71 
healthy controls (Table 6). The diagnosis of MS was based on McDonald's revised 
criteria and all diagnoses were definite (McDonald et al., 2001; Polman et al., 2005). 
CIS patients were defined as patients who had a first clinical episode suggestive of 
MS. All the patients were studied neurologically and blood samples were collected. 
The majority of the patients were studied during a remission (studies I-IV) and 
25/93 of RRMS and 7/29 of SPMS patients were studied during relapse (study I). 
None of the patients had received methyl prednisolon during the eight weeks prior to 
study entry. 43/93 of RRMS patients were treated with IFN-? and 6/93 with GA 
(table 6). The primary aim of these studies was not to evaluate the clinical efficiency 
of IFN-? treatment and therefore the timing of IFN-? injection prior to blood 
sampling was not recorded. Some of the MS patients were studied neurologically and 
by MRI one year after their baseline visit (n=89, study II), as well as two years after 
their baseline visit (n=21, study III).  
Clinical disease progression was evaluated by the Expanded Disability Status 
Scale (EDSS) (Kurtzke, 1983) at the baseline or changes in the EDSS score during 
the follow-up. Paraclinical disease progression was evaluated by volumes of T1 or 
changes in the volumes of T1 in the follow-up. Clinical disease activity was 
determined by calculating number of relapses proceeding two years (studies I-III) 
and paraclinical disease activity by the detection of Gd-contrast enhancing T1 lesions 
and volumes of FLAIR lesions by MRI (Studies II and III). 
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The study was approved by Ethics Committee of Tampere University Hospital and 
all subjects gave written informed consent.  
Table 6. Clinical characteristics of all patients  
 RRMS SPMS PPMS CIS All 
patients 
CTRL Total 
N 93 29 21 18 161 71 232 
Agea 36±11 48±9 57±9 34±9 40±13 37±12 39±13 
F/Mb 75/18 19/10 12/9 15/3 121/40 54/17 175/57 
Duration,a,c 5.1±4.6 9.9±8.0 11.9±8.4 1.9±1.9 7.1±6.6 - - 
Relapses a,d 0.9±0.6e 1.8±1.4 0.7±1.2 - 1.4±1.4 - - 
EDSSa 1.7±1.6 4.6±1.8 4.8±2.0 0.1±0.2 2.5±2.3 - - 
Therapyb       - 
  NT 44 25 21 18 108 - - 
  IFN 43 4 0 0 47 - - 
  GA 6 0 0 0 6 - - 
Abbreviations: RRMS relapsing-remitting multiple sclerosis; SPMS secondary progressive 
multiple sclerosis; PPMS primary progressive multiple sclerosis. CIS clinically isolated 
syndrome; CTRL controls; EDSS expanded disability status scale; NT no treatment; IFN 
interferon-?; GA glatiramer acetate. 
 
a Mean ± SD 
b Number of patients 
c Disease duration determined from the time of diagnosis for RRMS, SPMS and PPMS and 
from the first symptoms for CIS   
d All relapses during preceding two year 
e Disease activity from the studies I-III, pregnancy patients (study IV) disease activity were 
4.1±3.1(mean±SD) and were determined by total number of relapses experienced before the 
onset of the study. 
2. Molecular biology methods 
2.1 Blood sampling and RNA isolation from peripheral 
blood mononuclear cells (Studies I-IV) 
PBMC were separated in a VACUTAINER CPT cell preparation tube (Becton 
Dickinson and Company, Franklin Lakes, N.J., USA) according to the 
manufacturer’s protocol. Total cellular RNA was isolated from stored cell lysate with 
Qiagen’s RNase minikit (QIAGEN GmbH, Hilden, Germany) according to the 
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manufacturer’s instructions. DNA was removed with Qiagen’s RNase-Free DNase 
set. Total RNA was eluted to nuclease-free water and samples were stored -70 ºC. 
Sera were separated from blood and stored at -70 ºC. 
2.2 Gene expression analysis by Lightcycler (Study I) 
The expression of TRAIL mRNA could be determined in 46 patients and 17 controls 
in whom RNA was available. A relative quantitative real time polymerase chain 
reaction (RT-PCR) was performed with a LightCycler instrument (Roche 
Diagnostics GmbH, Mannheim, Germany). 1 µg of total RNA was reverse 
transcribed to complementary DNA (cDNA) with a Transcriptor First Strand cDNA 
Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany) following standard 
protocol with random hexamer primers.  
Table 7. TRAIL primers and probes  
Primer/Probe Sequence 
Forward primer 5’-AGAGAGTATGAACAGCCCCTG-3’ 
Reverse primer 5’-GTCCCAGTTATGTGAGCTGCTA-3’ 
Probe 1 5’-Red640-TTCTAACGAGCTGACGGAGTTGCCA-3’ 
Probe 2 5’- GGTTTCCTCAAGAGGTTCTCAAAAATCATC-FL-3’ 
Abbreviations: A adenine; C cytosine; G guanine; T thymine. 
 
2-µl cDNA was used in a total of 20 µl reaction volume for the PCR reactions. 
The final concentrations of the target reagents in the system were: 1 x LightCycler 
FastStart DNA Master HybProbe, 4 mM MgCl2, 0,5 µM each primer and 0,2 µM 
each probe. PCR cycling conditions were: denaturation at 95 ºC for 10 min, 
amplification 45 cycles, at 95º C for 15 seconds, at 55 ºC for 15 seconds and at 72 ºC 
for 15 seconds and cooling at 40 ºC for 30 seconds. Primers and probes for the 
LightCycler PCR were designed and prepared by TIB MolBiol (Berlin, Germany) 
(Table 7). As a reference gene we used human glucose-6-phosphate-dehydrogenase 
(h-G6PDH). Reference gene PCR was done at the same time and the same PCR 
conditions as the target gene by a LightCycler? h-G6PDH housekeeping gene set kit 
(Roche Diagnostic GmbH, Mannheim, Germany). The reference gene was selected 
by a LightCycler h-Housekeeping Gene Selection Set, which included five 
alternative reference genes. All reactions for target and reference genes were made as 
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duplicate. Quantitative RT-PCR results were calculated by a LightCycler Relative 
Quantification Software with efficiency correction (Roche Diagnostics GmbH). 
2.3 QRT-PCR using low density array (Study III) 
Total-RNA (1 µg) was reverse transcribed to cDNA using High capacity cDNA 
reverse transcription kit (Applied Biosystems, Foster City, CA, USA) with standard 
protocol. Gene expression analyses were done with TaqMan low-density array 
(LDA) (Applied Biosystems) using 7900HT Real-time PCR system (Applied 
Biosystems). Human apoptosis array was used to determine expression of 93 
apoptotic-molecules and three housekeeping genes from PBMC. Arrays were loaded 
with 4 ?l undiluted cDNA, 42 ?l H2O, and 50 ?l PCR Universal master mix and run 
according to the manufacturer’s instructions. Samples were run as duplicate.  
The expression data was analyzed with RQ manager software using comparative Ct 
method (??Ct). To normalize the results, the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used and two healthy control samples were 
used as calibrator in the data analysis. 
2.4 Flow cytometry analysis (Study I) 
PBMC for TRAIL membrane expression analyses was obtained from 9 RRMS 
patients and 6 healthy controls. PBMCs (2 x10 5) were incubated with mouse anti-
human CD3-APC-Cy7, CD4-PE-Cy7, CD8-APC, CD14-FITC and TRAIL-PE 
(Becton Dickinson, Franklin Lakes, NJ, USA) monoclonal antibodies for 20 min. As 
an isotype control, cells were incubated with mouse anti-human IgG1-APC-Cy7, 
IgG1-PE-Cy7, IgG1-APC, IgG1-FITC and IgG1-PE monoclonal antibodies. 
Thereafter cells were washed twice, resuspended in PBS, and analyzed with 
FACSAria flow cytometry and Facsdiva software (Becton Dickinson). Stainings 
were made in duplicate. Optimization of fluorescence compensation was made using 
BD CompBeads (Becton Dickinson). 
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2.5 Enzyme-linked immunosorbent assay (Studies I, II 
and IV) 
Levels of sTRAIL in undiluted sera were quantified by a Diaclone solid phase 
sandwich ELISA kit (# 850.770.096; Diaclone, Besancon Cedex, France). Detection 
limits were 64 pg/ml. TRAIL absorbancies were read with a Multiskan MS version 
4.0 spectrophotometer (Labsystems, Helsinki, Finland) at wavelength 450 nm. 
2.6 Luminex (Studies I, II and IV) 
The collected blood was allowed to clot for at least 30 minutes before separation. 
The blood containing tubes were then centrifuged for 15 minutes at 1600 x g. Sera 
were separated from the blood, aliquoted and stored at -70 ?C. 
The levels of sFas, sFasL and MIF were measured with a Human sepsis/apoptosis 
LINCOplex Kit (Linco Research, St. Charles, Missouri, USA) (Studies I, II, and 
IV), CCL2, CCL3, CCL4 and CXCL10 with a Human cytokine LINCOplex kit 
(Linco Research) (Study II) and IL-2, IL-6, IL-10, IL-12p70, IFN-? and TNF-? with 
High Sensitivity Human cytokine LINCOplex kit (Linco Research) (Study II). All 
the data were collected and analyzed using Bio-Plex suspension array system and 
Bio-Plex Manager software 4.1 (Bio-Rad laboratories, California, USA). A five-
parameter regression formula was used to calculate the sample concentration from 
the Human sepsis/apoptosis LINCOplex Kit and the High Sensitivity Human 
cytokine LINCOplex kit, and a four-parameter regression formula was used for the 
Human cytokine LINCOplex kit. All 96 well plates included samples from all 
disease subtypes and controls to minimize inter-assay variation. The same batch of 
monoclonal antibodies for the Bio-Plex Cytokine Assay System was used throughout 
the experiments; the inter-assay and intra-assay values are reported to be less than 
15% by the manufacturer. The percent recovery of standards ranged from the 90% to 
110% that was used as a detection limit for each protein. The lower detection limits 
were as follows: 12.2 pg/ml for sFas, sFasL and MIF, 16.0 pg/ml for CXCL10, 
CCL3 and CCL4, 3.2 pg/ml for CCL2, 0.13 pg/ml for IL-10, TNF-a, IL-6, IL-12p70, 
IL-2 and IFN-g.  
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3. Magnetic resonance imaging (Studies II and IV) 
All examinations were performed on a 1.5 Tesla MRI Unit (Siemens Avanto, 
Erlangen, Germany). The MRI protocol for this examination included a T1 weighted 
header followed by an axial T1- weighted magnetization prepared rapid gradient 
echo (MP-RAGE), and a T2-weighted turbo spin-echo (TSE), fluid attenuation 
inversion recovery (FLAIR), magnetization transfer contrasts (MTC), diffusion 
weighted imaging (DWI), and gadolinium enhanced T1 weighted MP-RAGE 
sequences. In this study, T1 weighted MP-RAGE, FLAIR and T2-weighted TSE 
images were used for volumetric analysis. For MP-RAGE, the imaging parameters 
were as follows: repetition time (TR) = 1160 ms; echo time (TE) = 4.24 ms; 
inversion time (TI) = 600 ms; slice thickness=0.9 mm; in-plane resolution = 
0.45*0.45 mm. In FLAIR, the following parameters were used: TR = 8500 ms; TE = 
100 ms; TI = 2500 ms; slice thickness= 5.0 mm; in-plane resolution = 0.45*0.45 mm. 
In TSE, the following imaging scheme was used: TR = 750 ms; TE = 115 ms; slice 
thickness= 3.0 mm; in-plane resolution = 0.90*0.90 mm. Volumetric segmentation of 
plaques in the brain was performed using semiautomatic software Anatomatic™ 
operating in a PC/Window 95 environment (Heinonen et al., 1998a; Heinonen et al., 
1998b) and the images were analyzed blindly. 
4. Cluster analysis (Study III) 
The gene expression patterns were used to cluster the samples and genes by two-way 
hierarchical clustering. Absolute expression change values ?1.5 and ?0.67 were used 
as cut-offs to define differentially expressed genes. Genes that showed ?1.5 and 
?0.67-fold change in their expression level compared to control were regarded to be 
upregulated and downregulated, respectively. Hierarchical clustering was applied to 
both axes with the Cluster program (Michael Eisen, 
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http://rana.lbl.gov/EisenSoftware. htm) using uncentered correlation as a similarity 
metric. Results were visualized with the TreeView program (Michael Eisen, 
http://rana.lbl.gov/EisenSoftware.htm). 
5. Statistical analyses (Studies I-IV) 
Statistical analyses were performed using SPSS version 14.0 (studies I-II) and 16.0 
(studies III-IV) for Windows (SPSS Inc., Chicago, Illinois, USA). Results of gene 
expression were calculated by using the independent samples T-test (study I) and the 
Mann–Whitney U test (Study IV). A p values less than 0.05 were considered 
statistically significant. Results of serum cytokines were tested by non-parametric 
analyses: the Kruskal–Wallis test for comparison of more than two unpaired groups 
(study III), the Mann–Whitney U Test for comparison of two unpaired groups 
(studies I-III), and the Wilcoxon test for paired groups (studies II-III). A p values 
less than 0.05 (studies I-II) or 0.01 (studies III) were considered statistically 
significant. Correlations between variables were tested by two-tailed non-parametric 
Spearman correlation analysis. Due to multiple correlation testing, a p values of less 
than 0.01 were considered significant. Correlations between variables were tested by 
two-tailed non-parametric Spearman correlation analysis and a p values of less than 
0.01 were considered significant (studies I-IV).  
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RESULTS 
1. Candidate immunological biomarkers (Studies I- 
III) 
1.1 Characterization of immune profiles in different 
subtypes of multiple sclerosis 
We characterized serum profiles of apoptosis-related molecules (sFas, sFasL, 
sTRAIL, TNF-?), chemokines (CCL2, CCL3, CCL4, CXCL10) and cytokines (MIF, 
IL-2, IL-6, IL-10, IL-12p70, IFN-?) in all the MS subtypes during the disease stable 
phase (Studies I and II). These molecules are considered to be important in the MS 
pathogenesis. Elevated serum levels of sFas, TNF-? and CCL2 in PPMS and 
decreased levels of MIF were found in RRMS when compared to CIS, controls and 
other MS subtypes (Study II, Table 8). The levels of apoptosis-related molecules 
sFasL, sTRAIL, chemokines CCL3, CCL4, CXCL10 or cytokines IL-2, IL-10, IL-6, 
IL-12p70, IFN-? did not differ statistically between the groups (p>0.01). 
In addition to the soluble form of the TRAIL, we also studied the membrane 
bound form of the TRAIL in peripheral blood CD4+ and CD8+ T cells and CD14+ 
monocytes. No differences in the surface expression of TRAIL on CD4+ and CD8+ 
T cells and CD14+ monocytes was found in the 9 MS patients and 6 healthy controls. 
The surface expression of TRAIL was detectable in less than 1 % of CD3+CD4+ or 
CD3+CD8+ T cells and in less than 5 % of monocytes. 
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Table 8. The levels of soluble molecules in different types of MS and CIS and controls. Median (25th-75th percentiles) 
(Study II) 
Molecule 
 
CDMS  
N=72 
RRMS  
N=33 
SPMS  
N=18 
PPMS  
N=21 
CIS  
N=17 
HC  
N=21 
Fas 5394.3 4612.8 d 5572.4 6787.6 c,d 4318.8  4824.9 c 
 (4343.7–6833.5) (4058.0–5940.7) (4388.3–6845.4) (5393.9–7709.2) (3320.0–5697.9) (3405.1–5638.1) 
FasL 94.1  90.6  96.2  111.2  83.6 80.4  
 (67.6–168.6) (58.1–161.6) (72.8–153.6) (71.5–191.9) (67.1–174.6) (56.6–129.1) 
MIF 195.0 a 138.2 b,d 225.8  290.7 d 167.3 378.5 a,b 
 (100.2–298.0)  (50.0–229.4)  (134.0–317.3) (189.3–449.3)  (97.8–268.2) (236.4–535.9) 
TRAIL 845.2  765.9  785.5  1032.0  902.3 738.7  
 (645.2–1603.0) (577.2–1728.9) (587.2–1106.0) (762.8–2036.1) (593.3–1170.5) (523.2–2260.8) 
CXCL10 98.9  95.7  90.5  106.9 65.9 106.9 
 (66.1–154.7) (68.1–155.6) (62.8–152.6) (74.7–212.9) (53.6–178.2) (55.1–130.7) 
CCL2 218.3  177.0 218.8  288.4 c 248.3 152.8 c 
 (154.7–371.4) (140.4–271.8) (157.0–331.0) (201.3–461.6) (165.7–332.0) (122.6–273.1)  
CCL3 50.9  37.3  55.7 45.4 72.6  51.4 
 (22.4–99.3) (21.6–96.3) (19.2–121.4) (27.0–164.7) (32.0–186.1) (27.7–122.8) 
CCL4 160.6  126.6  140.2 290.7  365.1  289.1  
 (24.6–835.5) (20.4–668.0) (17.0–873.8) (39.8–1054.6) (144.0–1188.5) (16.8–725.0) 
59 
 
Abbreviations: CDMS clinically definite MS (RRMS, SPMS and PPMS); RRMS relapsing-remitting MS; SPMS secondary progressive MS; PPMS 
primary progressive MS; CIS clinically isolated syndrome; HC healthy controls; Fas L Fas ligand; MIF macrophage migration inhibitory factor; TRAIL 
tumor necrosis factor -related apoptosis inducing ligand; CXCL C-X-C motif chemokine ligand; CCL C-C motif chemokine ligand; IL interleukin; TNF 
tumor necrosis factor. 
a Comparison between CDMS and HC group, the Mann-Whitney U Test p<0.01 
b Comparison between RRMS and HC group, the Mann-Whitney U Test p<0.01 
c Comparison between PPMS and HC group, the Mann-Whitney U Test p<0.01 
d Comparison between the PPMS and RRMS group, the Mann-Whitney U Test p<0.01 
 
 
IL-10 3.2  2.9 3.4  3.6  4.8 2.3 
 (1.6–7.1) (0.6–5.7) (1.8–7.7) (2.2–9.2) (1.2–25.9) (0.2–6.0) 
TNF-? 4.7  a 4.5 d 4.1  6.4 c,d 4.6  3.7 a,c 
 (3.7–7.3)  (3.4–6.5) (3.3–5.8) (4.4–8.9)  (3.5–6.6) (2.4–4.6)  
IL-6 7.0  4.9  7.1  8.8  3.6  4.1  
 (2.1–18.4) (2.0–21.5) (3.2–13.0) (1.6–26.7) (1.4–17.9) (2.0–9.3) 
IL-12p70 0.6  0.4 1.3 0.8  1.7 1.6 
 (0.1–3.0) (0.1–1.4) (0.4–5.4) (0.1–4.5) (0.3–9.1) (0.1–7.9) 
IFN-? 0.6  0.3  1.5  0.6 2.8  0.5 
 (0.3–3.5) (0.3–3.0) (0.3–4.1) (0.3–3.3) (0.3–25.5) (0.3–7.5) 
IL-2 0.6  1.2 0.6  0.4 1.5 2.1 
 (0.2–3.6) (0.2–3.6) (0.2–5.2) (0.2–2.4) (0.5–6.2) (0.2–6.1) 
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Table 9. Significantly upregulated genes (fold change ? 1.50 and p?0.01) 
in CIS, RRMS and controls. 
Gene Gene expression valuesa Fold changeb p-valuec 
 RRMS CIS Control RRMS CIS RRMS CIS 
 N=11 N=10 N=7     
BAD 1.38  
(1.00–3.85) 
1.06 
(0.93–1.15) 
0.84 
(0.75–1.00) 
1.64* 1.26 0.01 0.02 
BBC3 1.32  
(0.91–2.73) 
1.03 
(0.82–1.23) 
0.80 
 (0.52–1.00) 
1.65* 1.29 0.01 0.09 
BCL2L14 1.72  
(1.34–2.15) 
1.38 
(1.04–2.62) 
1.00 
(0.34–1.18) 
1.72* 1.38 0.01 0.03 
BNIP3 1.36  
(1.16–1.56) 
1.69 
(1.30–1.84) 
1.00 
(0.72–1.05) 
1.36 1.69* 0.05 0.01 
TNFRSF25 2.73  
(1.81–3.85) 
3.05 
(2.16–3.36) 
1.16 
(1.00–1.49) 
2.35* 2.63* 0.01 0.00 
IKBKE 1.50  
(1.05–1.90) 
1.55 
(1.33–1.62) 
1.00 
(0.95–1.14) 
1.50* 1.55* 0.01 0.01 
NFKBID 1.76  
(1.36–2.05) 
1.77 
(1.54–1.97) 
1.00 
(0.92–1.30) 
1.76* 1.77 0.01 0.03 
Abbreviations: RRMS relapsing-remitting multiple sclerosis; CIS clinically isolated syndrome; BAD 
BCL2-associated agonist of cell death; BBC3 BCL2 binding component 3; BCL2L14 Apoptosis 
facilitator Bcl-2-like protein 14; BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; 
TNFRSF25 tumor necrosis factor receptor superfamily member 25; IKBKE inhibitor of nuclear factor 
kappa-B kinase subunit epsilon; NFKBID nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor. 
a The expression values are medians and numbers in parentheses interquartile ranges (q1–q3). 
b Fold changes are calculated by comparing median gene expression values between patients and 
control.  
c P-values between MS subtype and controls from Mann-Whitney U test. 
 
Gene expression profiles of apoptosis-related genes in early MS patients were also 
examined (Study III). In RRMS, six genes including the Bcl-2 family (BAD, BBC3, 
BCL2L14), the death receptor pathway (TNFRSF25) and NF-?B family (IKBKE, 
NFKBID) were upregulated when compared to controls (Table 9). In CIS patients, 
three genes BNIP3, TNFRSF25 and IKBKE appeared to be upregulated in 
comparison to controls. Thereafter, expression of all the genes in RRMS, CIS, and 
controls were compared with cluster analysis (Figure 8). In RRMS, almost all of the 
genes were upregulated when compared to controls (Figure 8A). Comparison 
between CIS and controls showed upregulated several genes in two regions in the 
dendrogram in CIS (Figure 8B). These genes are listed in Table 3 in study III. 
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Figure 8. Hierarchical clustering showing relative gene expression comparing 
patients with RRMS (A) and CIS (B) to healthy controls. The gene 
expression patterns were used to cluster the samples and genes by two-
way hierarchical clustering. Absolute expression change values ?1.5 and 
?0.67 were used as cut-offs to define differentially expressed genes. 
Genes that showed ?1.5 and ?0.67-fold change in their expression level 
compared to control were regarded to be upregulated (red) and 
downregulated (green), respectively. 
1.2 Immunological biomarkers in relation to the 
clinical and subclinical multiple sclerosis disease 
activity and disability 
1.2.1 Candidate biomarkers of disease activity  
Biomarkers association to disease activity of RRMS and SPMS patients can be 
studied by several methods. In this study, clinical disease activity was determined by 
calculating number of relapses in the preceding two years (studies I-III) and 
paraclinical disease activity by the detection of Gd-contrast enhancing T1 lesions and 
volumes of FLAIR lesions by MRI (Studies II and III). In addition, candidate 
biomarkers associations to disease activity were also studied in samples that were 
collected during clinical relapse (Study I).  
Most of the samples and MRI scans in this study were collected during the disease 
stable phase. Correlation analyses between clinical disease activity and analyzed 
molecules did not reveal significant results. Also no associations were found between 
the volumes of FLAIR white matter lesions and soluble molecules in the whole MS 
group. However, in the combined group of patients with RRMS and SPMS, 
significant correlation was detected between the levels of IL-6 and the volumes of 
FLAIR lesions (r=0.368 p=0.009, n=51, study II). 
During relapse, the levels of sTRAIL and MIF were higher in untreated patients 
with relapse when compared to controls or untreated patients in remission (Study I, 
Figure 9). The levels of sFas and sFasL were without significant differences between 
these comparisons. 
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Figure 9. The median levels of sTRAIL (A), sFas(B), sFasL (C) and MIF (D) in 
sera of all MS patients (n=91), untreated MS patients during 
remission (n=32), IFN-? treated MS patients during remission (n=27), 
untreated MS patients during relapse (n=22), IFN-? treated MS 
patients during relapse (n=10) and healthy controls (n=26). The levels 
of cytokines are shown for each donor. IFN= interferon-?, NT= no 
treatment. Picture adopted from the article by Rinta et al., 2008, 
reproduced with permission of the publisher. 
Correlation analyses between gene expression and clinical disease activity showed 
a positive correlation for BCL2L1 (r=0.777, p=0.008) and FAS (r=0.763, p=0.010) in 
RRMS patients (study III). In addition, negative correlations were found between 
the volumes of FLAIR and nine of the apoptosis-related genes and four out of these 
nine genes correlated negatively with the volumes of T1 lesions. 
1.2.2 Candidate biomarkers of disease progression 
Disease progression was evaluated by EDSS score or the presence of new T1 
changes. Therefore, correlation analyses between immunological molecules and 
EDSS scores, progression index and the volumes of T1 lesions were performed. The 
expression of TRAIL mRNA correlated positively with EDSS score (r=0.38, 
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spearman p=0.01) and especially in the IFN-? treated RRMS patients in remission 
(n=21) the expression of TRAIL mRNA correlated positively with both EDSS score 
(r=0.59, spearman p=0.005) and progression index (r=0.56, p=0.009) (Study I,). 
Also, positive correlations between serum MIF and the EDSS score in the CDMS 
group (including all subtypes) were found (r=0.39, p=0.001, n=72, Figure 10A), but 
within the subtypes statistically significant correlations were not found (study II). 
At one-year follow up, EDSS score had increased by 31% of CDMS patients. 
Correlation analyses did not reveal significant changes between EDSS change and 
immunological findings. Therefore, to analyze the association between measured 
biomarkers and disease progression over the year, CDMS patients were divided into 
two groups: patients with disability progression (EDSS score increased more than 
0.5, n=20) and those with stable EDSS score (EDSS score unchanged, n=44). In the 
worsening patients, the levels of sFas and MIF were higher than in the stable group 
(Figure 10 B and C).  
Similarly, correlation analyses between T1 and FLAIR change and immunological 
molecules were not significant. To further evaluate the association between 
immunological responses and MRI changes consistent with neurodegeneration, the 
patients with RRMS and SPMS were divided into two groups: those with increased 
volumes of T1 over the year (progressed, ?T1?1.0 cm3, n=19) and stable ones 
(stable, ?T1< 1.0, n=27). Upregulated levels of sFas were found in patients with 
increasing T1 lesion volumes in comparison with the stable group (Figure 10 D). 
1.2.3 Conversion-related markers 
Over the one-year follow up, three out of seventeen CIS patients converted to 
CDMS, but we could not associate any of the immune markers to the conversion 
(study II). At the two-year follow-up, five out of ten patients fulfilled the diagnostic 
criteria of MS and those converted patients showed upregulation of three genes 
(APAF, BIRC6, CFLAR) when compared to controls (study III). 
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Figure 10. Association the levels of MIF and sFas to disease progression. 
(A) Correlations between baseline EDSS score and the levels of MIF in 
clinically definite MS (CDMS) group. (B-C) Increased levels of sFas and 
MIF were found in patients with disability progression in CDMS group. 
CDMS patients were divided into two groups: patients with disability 
progression (EDSS score increased more than 0.5, n=20) and those 
without progression of disability (EDSS score unchanged, n=44) over one 
year follow-up. (D) Upregulated levels of sFas were found in those RRMS 
and SPMS patient whose T1 lesion volumes increased in comparison to 
stable group of patients. RRMS and SPMS patients were divided in the 
two groups: those with increased volumes of T1 from baseline to one-year 
follow-up (progressed, n=19) and those with unchanged T1 volumes 
(stable, n=27).The length of the box represents the interquartile range 
within which 50% of the values were located. The line through the middle 
of each box represents the median. The error bars show the minimum and 
maximum values (range). Modified from Hagman et al., 2011. 
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2. Reconstitution of immune activity after 
pregnancy (Study IV) 
The study was undertaken to understand whether the postpartum disease activation of  
MS is associated with quantitative changes of apoptotic molecules in serum. Samples 
were obtained during the late pregnancy and postpartum from 19 RRMS patients and 
14 controls. The levels of sTRAIL and sFasL increased from the pre- to postpartum 
periods in  both groups (Figure 11). Moreover, in both pro- and postpartum situations 
the levels of sTRAIL were lower in RRMS patients than in controls. Comparing the 
apoptosis-related molecules changes (?) from late pregnancy to postpartum showed 
smaller changes in the sTRAIL in MS patients than in controls.  
No correlations were found between the levels of serum apoptotic molecules and 
annualized relapse rate or EDSS score, or changes (?) in the levels of apoptotic 
proteins with annualized relapse rate or EDSS score (p>0.01). In order to further 
explore the relationship between quantitative changes in the apoptotic molecules and 
activity of MS, the patients were divided into an active group (n=11, up to three 
relapses after pregnancy and a stable group (n=7, no relapses). Comparison between 
these groups showed that the patients with active MS had smaller ?FasL than the 
patients with inactive disease.  
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Figure 11. The levels (ng/ml) of sTRAIL (A-B), sFasL (C-D), sFas (E-F) and 
MIF (G-H) during late pregnancy (prepartum) and after delivery 
(postpartum) in MS (A, C, E and G) and healthy controls (B, D, F and 
H). The levels of molecules are shown for each donor. The arrowhead 
indicates the mean value. Picture adopted from the article by Rinta et al., 
2010, reproduced with permission of the publisher. 
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DISCUSSION 
1. Candidate immunological biomarkers (Studies I- 
III) 
1.1 Characterization of immune profiles in different 
subtypes of multiple sclerosis and CIS 
1.1.1 Primary progressive multiple sclerosis 
 In this thesis, we showed altered expression of immune-profiles in MS subtypes in 
both protein and gene expression levels. At the protein level, we observed a robust 
increase in sFas, TNF-? and CCL2 concentrations in PPMS patients that is 
consistent with the presence of inflammatory activity in this subtype. Previously, it 
was suggested that the PPMS subtype is a predominantly noninflammatory subtype, 
since new Gd-enhancing lesions are rare or absent and ongoing neurodegeneration is 
not correlated with the number or appearance of new focal white matter lesions 
(Bradl and Lassmann, 2009). Current DMT have little or no beneficial effect in the 
progressive stage of the disease. Therefore, it has been suggested that 
neurodegenerative events in the chronic progressive patients develop independently 
from inflammation. However, the most recent clinical trial on the efficacy of 
Rituximab in PPMS indicated delayed time to confirmed disease progression in 
Rituximab-treated patients with disease activity on MRI and this supports the 
concept of the inflammatory nature of PPMS patients (Hawker et al., 2009). 
The involvement of the Fas-FasL system in the pathogenesis of MS has been 
suggested by several authors (Zipp, 2000; Pender, 2007), but the exact role of sFas 
and sFasL in pathogenesis of MS is still not known. Fas-FasL is one of the death 
receptor-ligand systems of T cells that are crucial in the apoptotic signaling pathway 
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(Askenasy et al., 2005). In particular, death receptor Fas defects have been reported 
in the T lymphocytes of MS patients, and especially in the chronic progressive 
subtype. These defects were considered to promote the survival of autoreactive T 
cells (Comi et al., 2000; Sharief, 2000a). The soluble forms of Fas have been shown 
to inhibit apoptotic events in T cells (Aktas et al., 2006). Our observation of 
increased sFas in PPMS is in line with previous data thus favoring the concept of 
dysregulated Fas-mediated apoptosis in MS (Ciusani et al., 1998; Boylan et al., 
2001). In addition, TNF-? and CCL2 have been identified in active MS lesions 
(Selmaj et al., 1991) and increased levels of TNF-? in sera and CSF together with 
intrathecal synthesis of CCL2 have been reported in PPMS (Sharief and Hentges, 
1991; Hohnoki et al., 1998). TNF-? is a well-known trigger of the apoptosis of 
oligodendrocytes (Watzlawik et al., 2010), while CCL2 is involved in the 
recruitment of monocytes and T cells from blood to brain parenchyma (Mahad and 
Ransohoff, 2003).  
Taken together, our findings of increased levels of sFas, TNF-? and CCL2 in sera 
of PPMS patients together with earlier evidence are consistent with the involvement 
of these molecules in the pathogenesis of this subtype. This study also supports the 
hypothesis that the inflammation is present also in the PPMS subtype. Therefore, 
identification of immunological subtypes more carefully in this disease form may 
allow development of immunomodulatory therapies for PPMS patients.  
1.1.2 Relapsing-remitting multiple sclerosis and clinically 
isolated syndrome 
The gene expression analyses also showed aberrant immune profiles in RRMS and 
CIS patients. In RRMS, six proapoptotic genes that are members of the Bcl-2 and 
NF-K? families or included death receptor pathway were upregulated. Three of these 
genes are members of the Bcl-2 family, which are present on the mitochondrial 
membrane and include both pro- and antiapoptotic molecules. The balance between 
such pro- and antiapoptotic Bcl-2 family molecules determines the death or survival 
of cells (Brenner and Mak, 2009). Since one of the important roles of the immune 
system is to maintain peripheral homeostasis and thereby prevent inflammatory-
driven pathogenetic events (Gregersen and Behrens, 2006), upregulation of 
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proapoptotic Bcl-2 family genes in RRMS indicates that the regulatory effects of the 
immune system are directed to the enhancement of apoptotic events in peripheral 
blood.  
Furthermore, enhanced gene expression of TNFRSF25 was found in both RRMS 
and CIS. TNFRSF25 is a receptor of the TNF-family that is constantly expressed in 
T lymphocytes, and its expression is strongly upregulated after T-cell activation 
(Croft, 2009). TNFRSF25 may either activate NF–?B and MAP-kinase signaling or 
alternatively trigger caspase activation and programmed cell death (Chinnaiyan et al., 
1996; Wen et al., 2003).  
Upregulated gene expression of IKK and NF-?B-related molecules was also 
found in RRMS and CIS. NF-?B related genes are essential in promoting 
proinflammatory events in immune cells (Krammer et al., 2007). IKBKE is the IKK-
related kinase that has an essential role in innate immunity through activation of NF-
?B, interferon regulatory factor (IRF)-3 and IRF7 (Hacker and Karin, 2006). The 
expression of BCL2 and BCL2L1 is also largely regulated by TCR mediated NF-?B 
activation.  
In summary, aberrant gene expression profiles were seen in RRMS as well as CIS 
patients that suggest that apoptotic events are an important part of the MS 
pathogenesis. Upregulation of these pro- and anti-apoptosis molecules indicate the 
regulatory effect of the immune system in maintaining peripheral homeostasis and 
thereby preventing pathogenetic events. 
1.2 Immunological biomarkers in relation to the 
multiple sclerosis clinical and subclinical disease 
activity and disability 
1.2.1 Candidate biomarkers of disease activity  
The primary aim in the field of biomarkers is to find sensitive, relatively inexpensive 
blood or CSF biomarkers that can detect inflammatory activity as well as the degree 
of neurodegeneration. MRI and OCB in CSF is the main paraclinical tool used in 
clinical practice (McFarland, 2009), but clinicoradiological correlations have been 
generally weak thus far (Barkhof, 2002). 
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Serum levels of MIF were upregulated during relapse and downregulated during 
remission and that may indicate the importance of this molecule as a disease activity 
marker. In line with our observation, Niino et al., have detected increased levels of 
MIF in CSF from relapsing multiple sclerosis patients (Niino et al., 2000). MIF is 
released from cytoplasmic stores following stimulation by endotoxin, exotoxin and 
cytokines such as TNF and IFN-? and it can act in an auto- and paracrine fashion to 
stimulate its own synthesis and the synthesis of other proinflammatory mediators 
(Calandra et al., 1994). Studies using EAE have shown that MIF induces the 
accumulation of encephalitogenic T cells in the CNS thus facilitating the 
development of EAE (Denkinger et al., 2003; Kithcart et al., 2010). More recently, 
MIF was identified as a non-cognate ligand of the chemokine receptors CXCR2 and 
CXCR4 (Bernhagen et al., 2007). Taken together, these observations suggest that 
MIF is associated with disease activity and can strengthen the effects of other 
proinflammatory stimuli. Upregulated serum sTRAIL during relapse indicates that 
determination of this cytokine may be useful in the evaluation of MS disease activity. 
TRAIL is an anti-inflammatory molecule and upregulated TRAIL in sera may exert 
neuroprotective effects through inhibition of proinflammatory activity during relapse. 
However, this concept is in contrast with an observation of apoptosis-inducing 
effects of TRAIL in human brain reported by Nitsch et al. (Nitsch et al., 2000).  
One tenth of the expression of apoptosis-related genes in this study correlated 
negatively with the volumes of FLAIR lesions. Among these molecules antiapoptotic 
BIRC2 and BIRC3 correlated with the volumes of FLAIR and T1 lesions, which is 
consistent with the presence of inflammatory activity in the brain. BIRC2 and BIRC3 
are members of the inhibitor of apoptosis proteins (IAP) family that prevents 
apoptosis by interfering in the activation of caspases and ubiquitin-dependent 
signaling events that regulate activation of NF-?B transcription factor (Gyrd-Hansen 
and Meier, 2010). It has been reported that protein expression of BIRC2, BIRC3, 
XIAP, BIRC5 in mitogen-stimulated T cells from active RRMS patients has been 
elevated and that these levels were associated with resistance of T cells to apoptosis 
(Sharief and Semra, 2001a; Sharief and Semra, 2001b). Moreover, a very recent 
study has shown that BIRC2 and BIRC3 mRNA levels were elevated in T cells in 
active MS patients (Hebb et al., 2008). In the present study, we could not find any 
differences in the gene expression levels of BIRCs between MS patients and 
controls, but a negative correlation between the expression of BIRC2 and BIRC3 
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with volumes of T1 and FLAIR lesions is consistent with the presence of 
inflammatory activity in the brain. It is noteworthy that the expression of FAS genes 
also correlated with the number of relapses and the volumes of FLAIR lesions. FAS-
FASL signaling plays a critical role in controlling the immune system, indicating the 
importance of FAS in inflammation (Zipp, 2000). 
Taken together, this thesis showed that MS disease activity was associated with 
upregulation of serum MIF and TRAIL and suggests that these molecules may be 
candidate biomarkers for disease activity. These findings need to be confirmed with 
larger patient cohorts and longer follow-up times. 
 
1.2.2 Candidate biomarkers of disease progression  
The levels of sFas increased during the follow up in those patients whose EDSS 
score and T1 lesion volumes increased. T1 lesions represent axonal loss that 
contributes to the neurological disability in MS (Tomassini and Palace, 2009). 
Evidence on the predictive value of Fas in the evaluation of disease course has been 
contradictory (Zipp et al., 1998b; Lopatinskaya et al., 2006). One study reported an 
association between the increased levels of sFas in sera of patients with short-term 
disease progression (Zipp et al., 1998b), while a recent 10-year follow-up study 
reported an association between increased blood mRNA expression with favorable 
disease course in RRMS and SPMS (Lopatinskaya et al., 2006). Our observations of 
increased sFas in worsening patients support the concept of sFas promoting 
autoreactive T-cell survival that in turn is likely to facilitate neurodegenerative 
events. Moreover, the baseline EDSS score correlated with the expression of TRAIL 
mRNA and serum MIF and clinical disability progression at one year were 
associated with the baseline levels of MIF. 
It is important to recognize those patients who have a high risk of disability 
progression. Therefore biomarkers that would predict emergence of disability in 
invidual MS patient would allow more focused treatment decisions for those patients. 
These studies showed that disability progression was associated with increased 
TRAIL mRNA, MIF and sTRAIL and suggest that these molecules may be candidate 
biomarkers for disability progression. 
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1.2.3 Conversion-related markers 
Prognostic markers predicting the risk of transition from CIS to CDMS would have a 
strong influence on treatment decisions. Up to now, lesion load in the initial MRI of 
CIS patients and OCB in CSF has been the best validated prognostic paraclinical 
measure (Achiron and Barak, 2000; Brex et al., 2002; Fisniku et al., 2008; Rojas et 
al., 2010).We evaluated whether the changes in apoptosis-related genes are already 
detectable after the first demyelinating event, in which case they might be used as 
prognostic markers of a transition to definite MS. Hierarchical cluster analysis 
showed upregulation of several genes in CIS patients, and three of these genes were 
even more upregulated in those subjects who converted to definite MS. These three 
genes can activate (APAF) or inhibit (BIRC6, CFLAR) caspases, thus promoting 
proinflammatory events that may be responsible for immune cells’ transmigration to 
the CNS. All these upregulated genes could be useful in the prediction of conversion 
in the early phase of the disease. Since only a limited number of patients could be 
included in this exploratory study, the data obtained should be interpreted with 
caution. These preliminary interesting findings need to be confirmed by larger 
patient series with longer follow-up periods. 
2. Reconstitution of immune activity after 
pregnancy (Study IV) 
Pregnancy influences disease disease activity of MS patients. The relapse rate 
declines during late pregnancy and increases again after delivery (Confavreux et al., 
1998). In spite of recent progress in the understanding of the modulatory effect of 
pregnancy on MS, very little is known about the detailed molecular mechanisms of 
this phenomenon (Offner and Polanczyk, 2006). In the present study we analyzed 
whether the activation of MS after delivery is associated with quantitative changes of 
apoptotic molecules in serum. The levels of serum sTRAIL and sFasL increased 
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postpartum compared to late pregnancy samples both in MS and controls. In line 
with this observation we earlier reported an association between elevated sTRAIL 
and disease activity in RRMS (Rinta et al., 2008). TRAIL inhibits proliferation of 
activated T cells (Lunemann et al., 2002; Diehl et al., 2004) and it has been shown to 
have a beneficial effect in the EAE model (Hilliard et al., 2001). However, in the 
CNS, TRAIL mediates apoptosis of brain cells (Nitsch et al., 2000; Dorr et al., 2002; 
Aktas et al., 2005; Dorr et al., 2005). Postpartum upregulation of sTRAIL in both MS 
patients and controls may be associated with the physiological immune activation 
known to occur after pregnancy and may reflect a tendency of the immune system to 
control inflammatory responses. The smaller increase of sTRAIL from late 
pregnancy to postpartum in MS compared to controls may be a factor associated with 
inadequate inhibition of T-cell reactivation after pregnancy. 
The significant increase in the levels of sFasL from pre- to postpartum periods in 
both patients with MS and their controls may be associated with increased immune 
activation. This is in accordance with our data showing increased levels of sFasL 
during MS relapses (Rinta et al., 2008) and results by other investigators reporting 
increased expression of FasL mRNA in blood cells during lesional activity 
(Lopatinskaya et al., 2003). The similar levels of sFas in pre- and postpartum 
samples of MS patients are consistent with previous data by Ehrlich et al (Ehrlich et 
al., 2007).  
Currently, we cannot predict which patients disease activity will increase after 
delivery. Therefore it would be important to find a biomarker that is associated with 
the postpartum disease activation. That would help mothers to decide whether initiate 
early DMT to minimize risk of relapses or continue breast-feeding. In this study, we 
showed that there was a slight difference in the levels of ?sFasL in those patients 
who relapsed after delivery and those who remained stable. 
Taken together, upregulation of sTRAIL and sFasL from pregnancy to the 
postpartum situation both in patients with MS and healthy women is the main 
observation of our study. Since these molecules are secreted by immune cells in 
activation-dependent manner, it is most likely that the quantitative changes detected 
in this study are due to T-cell activation occurring during physiological reactivation 
of the mother’s immune system after pregnancy (Elenkov et al., 2001; Gilmore et al., 
2004). To clarify whether the TRAIL and sFasL could be used as a postpartum 
disease activity marker, this study needs to be repeated with the larger patient cohort. 
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SUMMARY AND CONCLUSIONS 
The aim of this study was to identify biomarkers in the blood that would reflect 
pathogenetic processes in MS and CIS and be used as biomarkers of disease activity 
and progression. 
 
The major findings of the study were: 
 
1. Altered expression of immune profiles in MS subtypes was found in both 
protein and gene expression levels. In PPMS, elevated sFas, TNF-? and 
CCL2 concentrations is consistent with the presence of inflammatory activity 
in this subtype. Therefore, identification of immunological subtypes more 
carefully in this disease form may allow development of immunomodulatory 
therapies for PPMS patients. In RRMS and CIS, atypical gene expression 
profiles involving genes of Bcl-2 and NF-?B families and death receptor 
pathway were identified. Upregulation of these pro- and anti-apoptosis 
molecules indicate the regulatory effect of the immune system in maintaining 
peripheral homeostasis and thereby preventing pathogenetic events. 
 
2. MS disease activity was associated with upregulation of serum MIF and, 
TRAIL, and disease progression was associated with increased TRAIL 
mRNA, MIF and sFas. These observations suggest that these molecules may 
be candidate biomarkers for disease activity and progression. 
 
3. In CIS, three out of 93 apoptosis-related genes were upregulated in those 
subjects who converted to definite MS. These three genes can activate 
(APAF) or inhibit (CFLAR, BIRC6) caspases. These upregulated genes could 
be useful in the prediction of conversion to MS. 
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4. sTRAIL and sFasL were upregulated in both MS patients and healthy women 
from late pregnancy to postpartum. The increase in sTRAIL was significantly 
smaller in the MS patients compared with the controls. Hence, activation of 
MS after delivery may be related to inadequate inhibition of T-cell 
reactivation after pregnancy in MS. 
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TNF-related apoptosis-inducing ligandphocytes may lead to harmful immunoreactivity in MS. We analyzed apoptosis-
related molecules including TRAIL, sFas, sFasL and MIF in the blood of 117 MS patients and controls to answer
whether these molecules may be used in the evaluation of disease activity and immunomodulatory effect of
IFN-β. Increased levels of sTRAIL, sFasL and MIF were found in sera of untreated patients with MS relapse
indicating their association with MS disease activity. IFN-β treated patients in remission had increased TRAIL
mRNA, sTRAIL, sFaL and MIF that most likely reﬂect bioactivity of IFN-β.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is an immune-mediated disease of the
central nervous system (CNS) initiated by recruitment of activated T
cells and macrophages to the brain (McFarland and Martin, 2007). A
failure of autoreactive immune cells to undergo apoptosis in MS may
lead to inappropriate persistence of these cells and cause harmful
immunoreactivity within the CNS (Okuda et al., 2006; Saresella et al.,
2005; Sharief, 2000;Wosik et al., 2007). Since thepresence of apoptosis-
relatedmolecules in blood is thought to reﬂect the pathological process
in the CNS, determination of these molecules may be useful in
evaluation of disease activity and therapeutic responses.
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a newmolecule among the potential biomarkers in MS (Gilli
et al., 2006; Wandinger et al., 2003). Upregulated expression of TRAIL
messenger RNA (mRNA) has been reported in peripheral blood
mononuclear cells (PBMC) of interferon-β (IFN-β) treated relapsing
remitting MS (RRMS) patients responding to treatment (Gilli et al.,
2006;Wandinger et al., 2003). Based on these observations it has been
suggested that TRAIL could be used as a biomarker reﬂective of
response to IFN-β treatment in MS (Wandinger et al., 2003). InmentofNeurology, Finn-Medi 3,
8 3 311 66692.
l rights reserved.experimental disease models including experimental autoimmune
encephalomyelitis (EAE), HIV encephalopathy and stroke, TRAIL has
been shown to mediate apoptosis of brain cells (Aktas et al., 2005;
Martin-Villalba et al., 1999; Miura et al., 2003).
Fas ligand (FasL/CD154) is another member of the TNF family that
together with its receptor Fas (CD95), participates in the apoptotic
signalling pathway in the activated T cells (Askenasy et al., 2005).
Increased mRNA expression of Fas and FasL has been consistently
reported in the PBMC of RRMS patients (Gomes et al., 2003; Huang
et al., 2000), but the results on the levels of soluble Fas (sFas) in sera are
contradictory (Bilinska et al., 2003; Inoue et al., 1997; Mahovic et al.,
2004; Zipp et al., 1998b). Membrane-bound forms of Fas and FasL are
able to induce apoptosis of Tcells, while soluble forms inhibit apoptotic
events. This suggests that upregulated levels of sFas and sFasL may
prevent apoptosis of potentially pathogenic immune cells, which may
lead to their accumulation in the CNS.
Macrophage migration inhibitory factor (MIF), involved in many
inﬂammatory diseases, is secreted by activated T cells, macrophages
and a variety of nonimmune cells (Cvetkovic and Stosic-Grujicic,
2006). MIF is a pleiotropic inﬂammatory cytokine with broad target
cell speciﬁcity. MIF upregulates expression of adhesion molecules,
proinﬂammatory cytokines and toxic molecules (Cvetkovic and Stosic-
Grujicic, 2006). Increased expression of MIF has been reported in the
cerebrospinal ﬂuid (CSF) of patients with MS relapses (Niino et al.,
2000). Anti-MIF treatment of mice with EAE decreased accumulation
Table 2
Clinical characteristics of patients included in TRAIL mRNA analyses
Characteristic All MS
patients
MS Healthy
controlsNo treatment IFN-β
N=46 N=23 N=23 N=17
Disease course (RR/SP) 36/10 15/8 21/2 NA
Age (years)a 39.7±9.7 41.8±18.2 35.4±9.0 35.4±9.4
Gender (F/M) 32/14 15/8 17/6 17/9
Duration of disease (years)a 7.3±6.3 4.3±3.6 6.9±6.6 NA
No. of relapses/2 yearsa 1.6±1.5 1.1±1.1 1.7±1.1 NA
EDSSa 3.0±2.0 2.3±1.9 1.9±2.0 NA
Progression indexa,b 1.3±2.2 1.1±1.6 0.3±0.4 NA
RR relapsing remitting multiple sclerosis, SP secondary progressive MS, IFN-β
interferon-β, NA not available, EDSS expanded disability status scale.
a Mean±SD.
b EDSS/duration of the disease.
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ameliorated disease severity and accelerated recovery from the
disease (Denkinger et al., 2003).
The aim of this study was to examine whether the expressions of
TRAIL gene and the levels of sTRAIL, sFas, sFasL and MIF in sera of MS
patientsmay be used in the evaluation of disease activity and response
to IFN-β treatment in MS.
2. Subjects and methods
2.1. Subjects
The study included 117 subjects: 70 RRMS patients, 21 secondary
progressive MS (SPMS) patients and 26 healthy controls. Thirty seven
of 91 MS patients were treated with IFN-β and the remaining ones
were untreated. All IFN-β products were used: Avonex® (30 µg IFN-β-
1a intramuscular once a week), Rebif® (22 µg or 44 μg IFN-β-1a
subcutaneously (sc) three times a week) and Betaferon® (250 µg IFN-
β-1b sc every other day). Serum samples from 10/37 IFN-β treated
patients and 22/54 untreated patients were obtained at the time of
acute relapse before initiation of methylprednisolone (MP) treatment.
The clinical characteristics of these patients are shown in Table 1. The
diagnosis of MS was based on McDonald's criteria and all diagnoses
were deﬁnite (McDonald et al., 2001). Neurological disability was
evaluated by the Expanded Disability Status Scale (EDSS) (Kurtzke,
1983). None of the patients had received MP during the eight weeks
prior to study entry. The study was approved by Ethics Committee of
Tampere University Hospital and all subjects gave written informed
consent.
Based on clinical characteristics, IFN-β treated patients in remis-
sion were divided into responders (n=16) and partial responders
(n=7). Those subjects who had no further relapses and were without
deterioration in the EDSS during one-year IFN-β treatment were
deﬁned as drug responders and the remaining ones as partial
responders. Four patients that had been on IFN-β treatment for less
than three months could not be included into this subanalysis. Since
the evaluation of clinical efﬁciency of IFN-β treatment was not the
primary aim of this study, the presence of neutralizing antibodies was
not obtained and the timing of IFN-β injection prior to blood sampling
was not recorded.
Serum measurements were performed in 91 MS patients and 26
healthy controls (Table 1). Expression of TRAIL mRNA was analyzed
from the PBMC of 46 MS patients and 17 healthy controls (Table 2),
whilemembrane expression of TRAILwas analyzed in 9 RRMS patients
and 6 healthy controls.Table 1
Clinical characteristics of MS patients (n=91) and healthy controls (n=26)
Characteristic All MS
patientsa
Remission
No treatment
N=91 N=32
Disease course (RR/SP) 70/21 20/12
Age (years)d 40.0±12.2 42.5±16.1
Gender (F/M) 63/28 21/11
Duration of disease (years)d 6.4±5.9 5.4±5.7
No of relapses/2 yearsd 1.7±1.6 0.9±1.1
EDSSd 2.4+2.0 2.6±2.1
Progression indexd,e 0.89±1.6 1.1±1.5
Duration of treatment (years )d 2.6±2.4 NA
RR relapsing remitting MS, SP secondary progressive MS, IFN-β interferon-β, NA not availab
a 37 of the 91 patients were treated with IFN-β and the remaining ones were without im
b Patients had the following treatments: Avonex® (n=7), Betaferon® (n=11) and Rebif®
c Patients had the following treatments: Avonex® (n=2), Betaferon® (n=3) and Rebif® (
d Mean±SD.
e EDSS/duration of the disease.2.2. Total RNA isolation from PBMC and serum separation
PBMC were separated in a VACUTAINER CPT cell preparation tube
(Becton Dickinson and Company, Franklin Lakes, N.J., USA) according
to the manufacturer's protocol. Total cellular RNA was isolated from
stored cell lysate with Qiagen's RNase minikit (QIAGEN GmbH, Hilden,
Germany) according to the manufacturer's instructions. DNA was
removed with Qiagen's RNase-Free DNase set. Total RNAwas eluted to
nuclease-free water and samples were stored −70 °C. Sera were
separated from blood and stored at −70 °C.
2.3. Relative quantitative RT-PCR
The expression of TRAIL mRNA could be determined in 46 patients
and 17 controls in which RNA was available (Table 2). A relative
quantitative real time polymerase chain reaction (RT-PCR) was
performed with a LightCycler instrument (Roche Diagnostics GmbH,
Mannheim, Germany). 1 µg of total RNA was reverse transcribed to
complementary DNA (cDNA) with a Transcriptor First Strand cDNA
Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany)
following standard protocol with random hexamer primers. 2-µl
cDNA was used in a total of 20 µl reaction volume for the PCR
reactions. The ﬁnal concentrations of the target reagents in the system
were: 1×LightCycler FastStart DNA Master HybProbe, 4 mM MgCl2,
0,5 µM each primer and 0,2 µM each probe. PCR cycling conditions
were: denaturation at 95 °C for 10 min, ampliﬁcation 45 cycles, at
95 °C for 15 s, at 55 °C for 15 s and at 7 °C for 15 s and cooling at 40 °C forRelapse Healthy controls
IFN-βb No treatment IFN-βc
N=27 N=22 N=10 N=26
25/2 17/5 8/2 NA
35.6±9.4 40.3±9.0 37.3±8.5 36.0±9.7
20/7 16/6 4/6 17/9
7.0±6.3 6.7±6.3 7.9±4.1 NA
1.6±1.2 2.0±1.7 3.4±2.2 NA
1.9±1.8 2.6±1.3 3.2±1.8 NA
0.34±0.4 4.0±4.4 0.5±0.4 NA
2.3±2.4 NA 3.4±2.2 NA
le, EDSS expanded disability status scale.
munomodulatory treatment.
(n=9).
n=5).
Fig. 1. TRAIL mRNA expression in 46 all MS patients, 23 non-treated (NT), 23 IFN-β
treated MS patients (IFN) and 17 healthy controls (mean±SD). Relative expression of
TRAIL mRNA is shown for each donor.
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prepared by TIB MolBiol (Berlin, Germany). The following TRAIL
primers and probes were used: forward primer: 5′-AGAGAGTATGAA-
CAGCCCCTG-3′, reverse primer: 5′-GTCCCAGTTATGTGAGCTGCTA-3′,
Probe-5′-end labelled with acceptor dye Red 640: 5′-TTCTAACGAGCT-
GACGGAGTTGCCA-3′ and probe 3′-end labelled with ﬂuorescein: 5′-
GGTTTCCTCAAGAGGTTCTCAAAAATCATC-FL-3′. As a reference genewe
used human glucose-6-phosphate-dehydrogenase (h-G6PDH). Refer-
ence gene PCRwas done at the same time and the same PCR conditions
as the target gene by a LightCycler® h-G6PDH housekeeping gene set
kit (Roche Diagnostic GmbH, Mannheim, Germany). The reference
genewas selected bya LightCycler h-HousekeepingGene Selection Set,
which included ﬁve alternative reference genes. All reactions for target
and reference genes were made as duplicate. Quantitative RT-PCR
results were calculated by a LightCycler Relative Quantiﬁcation
Software with efﬁciency correction (Roche Diagnostics GmbH).
2.4. Determination of soluble TRAIL in sera
Levels of sTRAIL in undiluted sera were quantiﬁed by a Diaclone
solid phase sandwich ELISA kit (# 850.770.096; Diaclone, Besancon
cedex, France). Detection limits were 64 pg/ml. TRAIL absorbancies
were read with a Multiskan MS version 4.0 spectrophotometer
(Labsystems, Helsinki, Finland) at wavelength 450 nm.
2.5. Determination of soluble Fas, FasL and MIF using Bio-Plex suspension
array system
The levels of sFas, sFasL andMIF weremeasured simultaneously by
Bio-Plex suspension array system (Bio-Rad laboratories, Hercules, CA,
USA). A multiplex cytokine analysis kit was obtained from Linco
Research, Inc. (St. Charles, MO, USA). Samples were diluted 1 to 10 in
serum matrix and were run in duplicate according to the manufac-
turer's protocol. Data were collected and analyzed using the Bio-Plex
ManagerTM software 4.1 (Bio-Rad laboratories). A ﬁve-parameter
regression formula was used to calculate the sample concentrations
from the standard curve. The minimum detection limit for all the
cytokines was 12.2 pg/ml.
2.6. Cell-surface expression of TRAIL by multicolor FACS analysis
PBMC for TRAIL membrane expression analyses was obtained
from 9 RRMS patients and 6 healthy controls. PBMCs (2×105) were
incubated with mouse anti-human CD3-APC-Cy7, CD4-PE-Cy7, CD8-
APC, CD14-FITC and TRAIL-PE (Becton Dickinson, Franklin Lakes,
NJ, USA) monoclonal antibodies for 20 min. As an isotype control,
cells were incubated with mouse anti-human IgG1-APC-Cy7, IgG1-
PE-Cy7, IgG1-APC, IgG1-FITC and IgG1-PE monoclonal antibodies.
Thereafter cells were washed twice, resuspended in PBS, and
analyzed with FACSAria ﬂow cytometry and Facsdiva software
(Becton Dickinson). Stainings were made in duplicate. Optimization
of ﬂuorescence compensation was made using BD CompBeads
(Becton Dickinson).
2.7. Statistical analyses
Statistical analyses were performed using SPSS version 14.0 for
Windows (SPSS Inc., Chicago, Illinois, USA). Results of TRAIL mRNA
were normally distributed and group comparisons were made using
the independent samples T-test. Due to the skewed distributions of
serum cytokine levels, the group comparisons were made using the
Kruskal–Wallis and Mann–Whitney U test. A p value less than 0.05
was considered statistically signiﬁcant. Correlations between vari-
ables were tested by two-tailed non-parametric Spearman correla-
tion analysis. Due to multiple correlation testing, a p value of less
than 0.01 was considered signiﬁcant.3. Results
3.1. Expression of apoptosis-related cytokines in MS and controls
The expression analysis of TRAIL mRNA performed on 46 MS
patients and 17 healthy controls showed that the levels of this
cytokine were of the similar magnitude (Table 2, Fig. 1). Measurement
of soluble molecules performed from sera of 91 MS patients and 26
controls (Table 1 and Fig. 2) revealed higher levels of sTRAIL in MS
compared to controls (median: 1082.3 vs. 719.0 pg/ml, p=0.01), but no
differences were found in the levels of sFas, sFasL or MIF.
3.2. Relationship to MS disease activity
These analyses included 22 untreated MS patients with relapse, 32
untreated patients in remission and 26 controls (Table 1). Comparison
between patients at relapse with controls showed increased sTRAIL
(1374.3 vs. 719.0 pg/ml: pb0.001, and MIF (888.9 vs. 299.4 pg/ml,
pb0.001) in patients with relapse (Fig. 2A and D). The levels of these
cytokines in patients in remission and controls were without signiﬁcant
differences. Likewise, the levels of sFas and sFasL were without
differences between all studied groups.
Comparison between untreated patients with relapse and remission
revealed higher levels of sTRAIL (1374.3 vs. 726.6 pg/ml, pb0.001) and
MIF (888.9 vs.150.4 pg/ml,pb0.001) inpatientswith relapse (Fig. 2A and
D). However, the levels of sFas and sFasL were without signiﬁcant
differences between these two patient groups (Fig. 2B and C).
Comparison between RRMS patients at relapse (n=17) and remission
(n=20) showed increased levels of sFasL inpatientswith relapse (98.0 vs.
52.0, pg/ml, p=0.002). No differences were found in the expression of
TRAIL mRNA between patients in remission and controls (Fig. 1).
3.3. Relationship to IFN-β treatment
These analyses included 37 IFN-β treated patients (27 in remission
and 10with relapse) and 54 untreated patients (32 in remission and 22
with relapse) (Table 1). Higher expression of TRAILmRNAwas found in
IFN-β treated patients compared to untreated ones (2.0±1.3 vs. 1.3±
0.4; p=0.03, Fig. 1). Moreover, comparison between IFN-β treated
and untreated patients with remission showed higher levels of sTRAIL
(999.0 vs. 726.6 pg/ml, p=0.004), sFasL (median: 100.0 vs. 65.5 pg/ml,
p=0.04) and MIF (median: 414.9 vs. 150.4 pg/ml, p=0.02) in those that
were treatedwith IFN-β. But no differences were found in the levels of
sFas (Fig. 2). Comparison between treated and untreated patients at
relapse did not reveal differences in the levels of any apoptotic
cytokine.
Comparison between IFN-β responders (n=16) and partial respon-
ders (n=7) showed elevated levels of sFas (5633.4 vs. 4148.7 pg/ml,
Fig. 2. Themedian levels of (A) sTRAIL, (B) sFas, (C) sFasL and (D)MIF in sera of allMS patients (n=91), untreatedMS patients during remission (n=32), IFN-β treatedMSpatients during
remission (n=27), untreated MS patients during relapse (n=22), IFN-β treated MS patients during relapse (n=10) and healthy controls (n=26). The levels of cytokines are shown for
each donor. IFN = interferon-β, NT = no treatment.
138 S. Rinta et al. / Journal of Neuroimmunology 205 (2008) 135–141p=0.04) in IFN-β responders (Fig. 3). No differences in the levels of
TRAIL mRNA (2.2±1.4 vs. 1.8±1.0), sTRAIL (1291.7 vs. 981.5 pg/ml),
sFasL (100.0 vs. 78.4 pg/ml) andMIF (507.4 vs. 227.4 pg/ml)were found
between these patients groups.Fig. 3. The levels of (A) TRAILmRNA, (B) sTRAIL, (C) sFas, (D) sFasL and (E) MIF in INF-β respon3.4. TRAIL membrane expression
Nodifferences in the surface expression of TRAIL on CD4+ and CD8+
T cells and CD14+ monocytes was found in the 9 MS patients and 6ders and partial responders. The levels of apoptotic molecules are shown for each donor.
139S. Rinta et al. / Journal of Neuroimmunology 205 (2008) 135–141healthy controls that could be included in these analyses. The surface
expression of TRAILwas detectable in less than 1% of CD3+CD4+ or CD3+
CD8+ T cells and in less than 5% of monocytes (Fig. 4).
3.5. Correlations
The clinical relevance of detected immunological ﬁndings was
explored by correlating these data to clinical characteristics of the
patients. In the group including all 91 MS patients the expression of
TRAIL mRNA correlated positively with EDSS (r=0.38, spearman
p=0.01). In the IFN-β treated RRMS patients in remission (n=21) the
expression of TRAIL mRNA correlated positively with both EDSS
(r=0.59, spearman p=0.005) and progression index (r=0.56, spear-
man p=0.009, Fig. 5A and C).
4. Discussion
In MS a failure in apoptosis of autoreactive T cells may lead to
increased immunoreactivity within the CNS that may damage myelin,
oligodendrocytes, and neurons (Zipp, 2000). Since the presence of
apoptosis-related molecules in peripheral blood may reﬂect apoptotic
events in the CNS, determination of such molecules may be useful in
evaluation of disease activity and response to treatment. The aim of
this study was to examine whether the expressions of the TRAIL gene
and the levels of sTRAIL, sFas, sFasL andMIF in sera of MS patients may
be used for these purposes and whether the IFN-β treatment
modulates their expressions. In this study we found increased levels
of sTRAIL, sFasL and MIF in untreated patients with MS relapse,
indicating an association of these molecules with MS disease activity.Fig. 4. Expression of membrane-bound TRAIL in freshly isolated PBMC fromMS patients and con
according to forward light scatter and side scatter parameters. CD3+populationwas gated fromhi
(D) CD3+CD4+TRAIL+, (E) CD3+CD8+TRAIL+, and (F) CD14+TRAIL+ populations shown in the ﬁg
analyses.The upregulated levels of TRAIL mRNA, sTRAIL, sFasL and MIF IFN-β
treated patientsmost likely reﬂecting the bioactivity of this treatment.
Until now the results on TRAIL mRNA and sTRAIL in sera of
untreated MS patients have been contradictory (Buttmann et al.,
2007; Gilli et al., 2006; Huang et al., 2000). Upregulated expression of
TRAIL mRNA in RRMS has been reported by Huang et al., but this could
not be conﬁrmed by others. The lack of differences in the levels of
TRAIL mRNA or sTRAIL in MS patients and controls detected in this
study is in line with previous reports. In addition, the upregulated
levels of sTRAIL seen in patients at relapse indicate that determination
of this cytokine may be useful in the evaluation of MS disease activity.
TRAIL is an anti-inﬂammatory molecule, upregulated TRAIL in sera
may exert neuroprotective effects through inhibition of proinﬂamma-
tory activity during relapse. However, this concept is in contrast with
an observation of apoptosis-inducing effects of TRAIL in human brain
reported by Nitsch et al. (2000). The expression of TRAIL on the surface
of T cells and monocytes from blood of MS patients and controls was
less than 5%, corresponding to earlier data showing low expression of
TRAIL in freshly isolated PBMC (Arbour et al., 2005; Kayagaki et al.,
1999).
MIF has been reported to upregulate expression of adhesion
molecules, proinﬂammatory cytokines and toxic molecules thus
facilitating penetration of autoreactive T cells into the CNS with
following induction of apoptosis of neural tissue (Cvetkovic and
Stosic-Grujicic, 2006). Increased level of MIF in sera of our patients at
the time of MS relapse is consistent with proinﬂammatory activity of
this cytokine. This observation is also in line with data by Niino et al.
who showed upregulated levels of MIF in the CSF of MS patients with
acute relapse (2000).trols. Lymphocyte andmonocytes populationswere identiﬁed in the total PBMC population
stograms and (A) CD3+CD4+TRAIL+ cell populations, (B) CD3+CD8+TRAIL+, (C) CD14+TRAIL+,
ure from RRMS patient (A–C) and healthy control (D–F). These proﬁles are representative
Fig. 5. Correlations between EDSS score and TRAIL mRNA in (A) IFN-β treated RRMS and (B) untreated RRMS patients and progression index and TRAIL mRNA in (C) IFN-β treated
RRMS and (D) untreated RRMS patients.
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is crucial in the apoptotic signalling pathway (Askenasy et al., 2005).
Defective function of Fas in T cells in MS has been reported earlier
(Comi et al., 2000; Okuda et al., 2006), but the exact role of sFas and
sFasL in pathogenesis of MS is still not known. Increased level of sFasL
in sera of RRMS patients with relapse detected in this study suggests a
failure in Fas–FasL apoptosis pathway of autoreactive T cells. This in
turn may facilitate accumulation of these T cells into the CNS with
subsequent development of clinical disease activity. It is noteworthy
that increased expression of FasL mRNA in blood cells during lesional
activity has been earlier reported (Lopatinskaya et al., 2003). The lack
of differences in the levels of sFas between patients with MS relapse
and remission and between MS patients and controls found in the
present study is consistent with results by Ciusani et al. (1998) and
Inoue et al. (1997), but in contrast with those of Zipp et al. (1998b)
who reported elevated levels of sFas in sera in RRMS. The control
group in the study by Zipp et al. included patients with other
neurological diseases in addition to healthy individuals, which may be
a factor explaining the discrepancy.
In the present study we were able to conﬁrm previous observa-
tions of upregulated sTRAIL in IFN-β treated patients (Buttmann et al.,
2007; Gilli et al., 2006; Santos et al., 2006; Wandinger et al., 2003). In
addition, elevated levels of sFasL and MIF were detected in IFN-β
treated patients. The presence of upregulated apoptotic molecules in
sera of IFN-β treated patients most likely reﬂects immunomodulatory
activity of IFN-β. Based on these results inhibition of activated T cells
by TRAIL could be one of the mechanisms responsible for beneﬁcial
effect of IFN-β. Increased levels of sFasL and MIF in IFN-β treated
patients in remission compared to untreated MS group is most likely
due to more active disease in treated group (1.6 relapses in IFN-β
group vs. 0.9 relapses in untreated group before 2 years preceding
sampling). The presence of similar levels of sFas in IFN-β treated and
untreated MS patients is in line with earlier reports thus suggesting
that initiation of IFN-β therapy causes only transient increase in levels
of circulating sFas (Boylan et al., 2001; Zipp et al., 1998a).
The results on the signiﬁcance of TRAIL in evaluation of treatment
responses have been contradictory (Buttmann et al., 2007; Gilli et al.,
2006; Santos et al., 2006; Wandinger et al., 2003). Wandinger et al.reported that TRAIL could be used as a response marker for IFN-β
therapy (Gilli et al., 2006; Wandinger et al., 2003), but others have not
been able to conﬁrm this observation (Buttmann et al., 2007; Gilli
et al., 2006). In the present cross-sectional study we could not
differentiate between responders and partial responders to IFN-β
based on the levels of TRAIL mRNA and sTRAIL in these groups. This is
accordance with Buttmann et al. (2007). Correlation between TRAIL
mRNA and EDSS or progression index in IFN-β treated RRMS patients
in remission found in this study contradicts with current under-
standing of neuroprotective effects of TRAIL, but this observation
needs to be conﬁrmed by other studies.
In conclusion, the present study was undertaken to explore
whether the expressions of the TRAIL gene and the levels of sTRAIL,
sFas, sFasL and MIF in the blood of MS patients may be used in
evaluation of disease activity and immunomodulatory effect of IFN-β
treatment. Based on our data upregulated sTRAIL, MIF and sFasL in MS
patientswith relapse reﬂect increased clinical disease activity. In IFN-β
treated patients increased levels of TRAIL, MIF and FasL are indicators
of bioactivity of this drug.
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Multiple sclerosis (MS) is an autoimmune disease of the central
nervous system (CNS) that is characterized by complex pathophysio-
logical processes including inﬂammation, demyelination, axonal loss
and remyelination (McQualter and Bernard, 2007). Currently, the
clinical assessments used in the treatment of MS are relatively crude
and depend mainly on relapses and changes in disability scores.
Magnetic resonance imaging (MRI) is the main paraclinical tool used
in clinical practice (McFarland, 2009), but clinicoradiological correla-
tions have been generally weak thus far (Barkhof, 2002). Likewise,
prognosticmarkers predicting a risk of transition from clinically isolated
syndrome (CIS) to clinically deﬁnite MS (CDMS) would have a strong
inﬂuence on treatment decisions. Up to now, lesion load in the initial
MRI of CIS patients has been the best validated prognostic paraclinical
measure (Brex et al., 2002, AchironandBarak, 2000, Fisnikuet al., 2008).
Due to these reasons, sensitivebiomarkers are needed for the evaluation
of disease activity and progression, predicting the disease course and
optimizing therapeutic responses inMS (Tumani et al., 2009, Harris and
Sadiq, 2009).
Themajority of blood andCSFmarkers analyzed thus far inMSreﬂect
both immune-inﬂammatory and neurodegenerative events, but theircorrelation with clinical aspects have been relatively weak (Tumani
et al., 2009, Harris and Sadiq, 2009). Cytokines and chemokines are
major regulators of inﬂammation that mediate the recruitment of
leukocytes into CNSwith the subsequent development of tissue damage
(McQualter and Bernard, 2007). Several chemokines including CCL2,
CCL4, CCL5, CXCL10, CXCL12, and CXCL13 and their receptors including
CCR1, CCR2, CCR5, CXCR3, and CXCR4 have been detected in the active
MS lesions, as well as in CSF and blood where they were considered to
reﬂect disease activity (Szczucinski and Losy, 2007). Moreover, recently
expression of CXCR3+ on circulating CD8+ cells was associated with
MRImeasurements of inﬂammatory activity and tissue destruction (Fox
et al., 2008). Interestingly, it has been reported that interferon (IFN)-β
can modulate the levels of several chemokines (CCL1, CCL2, CCL7,
CXCL10 and CXCL11) in blood and CSF, thus limiting the entry of
immune cells into the CNS (Cepok et al., 2009, Sellebjerg et al., 2009).
Altered levels of proinﬂammatory cytokines such as interleukin
(IL)-2, IL-12, IL-6, tumor necrosis factor (TNF) -α and IFN-γ, and of
regulatory cytokines such as IL-10, IL-4 and transforming growth
factor (TGF)-β in the blood and CSF of MS patients have also been
reported (Imitola et al., 2005). These were considered to reﬂect the
in vivo activity of inﬂammatory cells (Sospedra and Martin, 2005).
Some of these cytokines are associated with disease activity on MRI
(Fassbender et al., 1998, Petereit et al., 2003). In general, markers of
inﬂammation show rather poor correlation with clinical disease
progression and there are no data on any sufﬁciently long period
follow up (Tumani et al., 2009).
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important pathophysiological mechanism in MS (Zipp, 2000, Pender,
2007). Neuropathological evidence showing enhanced expression of
death receptors Fas (CD95), TNF-related apoptosis-inducing ligand
receptor 1 (TRAIL-R1), TRAIL-R2, TNF-R1, TNF-R2 and their ligands Fas
Ligand (FasL), TRAIL and TNF-α in MS together with expression of
apoptotic molecules in blood and CSF favors this concept (D'Souza
et al., 1996, Dowling et al., 1996, Bonetti and Raine, 1997, Cannella
et al., 2007). However, only a few studies have analyzed the potential
of these molecules to predict clinical outcomes of disease.
Our aim in this study was to identify biomarkers in the blood that
could reﬂect pathogenetic processes in MS and be used in clinical
practice when treating patients with MS. Therefore, the proﬁles of
several cytokines, chemokines and apoptotic molecules that are
considered to be involved in pathogenesis of MS were evaluated with
the aim of recognizing suchmolecules that could be used as biomarkers
of disease activity and progression in MS.
2. Patients and methods
2.1. Subjects
The studywas a one-year prospective follow-up study that included
altogether 110 subjects of whom 72 had CDMS according to revised
McDonald Criteria (McDonald et al., 2001, Polman et al., 2005), 17 had
CIS and the remaining 21 were healthy controls (HC). The CDMS group
included 33 patients with relapsing remitting MS (RRMS), 18 patients
with secondary progressive MS (SPMS) and 21 with primary progres-
siveMS(PPMS). CISpatientsweredeﬁnedaspatientswhohad theirﬁrst
demyelinating neurologic event suggestive of MS. Six patients had
discontinued the study after the baseline visit because of severe
disability (1 RRMS, 1 SPMS and 4 PPMS) and two RRMS patients were
not willing to continue. The study was approved by the Ethics
Committee of Tampere University Hospital and all subjects gave
informed consent. All patients underwent neurological and MRI
examination at the baseline and one year after enrollment. The bloodTable 1
Clinical characteristics of patients with MS and healthy controls.
Characteristics CDMSf RRMS
Number of patients, baselinea 72 33
Gender F/Ma 48/24 24/9
Age (years)b 46 (38–54) 39 (30–44)
Time since ﬁrst symptoms (years)b 13.9 (6.7–19.1) 8.2 (4.0–12.7
Age at onset (years)b 30 (25–38) 27 (24–34)
Disease duration (years)b 5.8 (1.3–12.3) 2.8 (1.1–7.1)
Progression indexb,c 0.5 (0.2–1.4) 0.4 (0.2–1.4)
EDSS, baselineb 3.0 (1.5–6.0) 1.5 (1.0–2.5)
EDSS, 1-yearb 3.0 (1.5–6.0) 1.5 (1.5–2.6)
Number of relapses, baselinea,d
0 23 7
1 12 11
2–5 16 15
Number of relapses, 1-yeara,e
0 34 18
1 10 9
2–5 3 3
Treatment, baseline NT/IFN/GAa 49/20/3 11/19/3
Treatment, 1-year NT/IFN/GAa 45/17/2 11/17/2
Duration of the treatments, baseline (months)b 16 (7–38) 14 (6–32)
CDMS clinically deﬁnite MS group, RRMS relapsing remitting MS, SPMS secondary progre
controls, EDSS expanded disability status scale, IFN interferon-β, GA glatiramer acetate, NT
a Number of patients.
b Median (25th–75th percentiles).
c EDSS/duration of the disease (years).
d All relapses during preceding 2 years.
e All relapses during preceding year.
f Group comprising RRMS, SPMS and PPMS patients.was drawn on the same day as the neurological examination. The
clinical evaluation included the determination of anExpandedDisability
Status Scale (EDSS) score (Kurtzke, 1983), number of relapses 2 years
before study entry, disease duration, progression index, and different
immunomodulatory treatments that are summarized in Table 1. Age
and gender-matched healthy controls were recruited from the staff of
the University of Tampere or Tampere University hospital.
2.2. Determination of cytokines, apoptotic molecules and chemokines
The collected blood was allowed to clot for at least 30 min before
separation. The blood containing tubes were then centrifuged for
15 min at 1600 xg. Sera were separated from the blood, aliquoted and
stored at −70 °C. The sera were analyzed for 14 different proteins
including cytokines TNF-α, IL-10, IL-6, IL-12p70, IL-2, IFN-γ, chemo-
kines CXCL10, CCL2, CCL3, CCL4 and apoptotic molecules sTRAIL, sFas,
sFasL, MIF. Levels of sTRAIL in undiluted sera were quantiﬁed by using
a Diaclone solid phase sandwich ELISA kit (#850.770.096; Diaclone,
Besancon Cedex, France) according to the manufacturer's protocol.
Detection limits were 64 pg/ml. TRAIL absorbancies were read with a
Multiskan MS version 4.0 spectrophotometer (Labsystems, Helsinki,
Finland) at wavelength 450 nm.
The levels of sFas, sFasL and MIF were measured with a Human
sepsis/apoptosis LINCOplex Kit (Linco Research, St. Charles, Missouri,
USA), CCL2, CCL3, CCL4 and CXCL10 with a Human cytokine LINCOplex
kit (Linco Research) and IL-2, IL-6, IL-10, IL-12p70, IFN-γ and TNF-α
with High Sensitivity Human cytokine LINCOplex kit (Linco Research).
All the data were collected and analyzed using Bio-Plex suspension
array system and Bio-Plex Manager software 4.1 (Bio-Rad laboratories,
California, USA). A ﬁve-parameter regression formula was used to
calculate the sample concentration from the Human sepsis/apoptosis
LINCOplex Kit and the High Sensitivity Human cytokine LINCOplex kit,
and a four-parameter regression formula was used for the Human
cytokine LINCOplex kit. All 96 well plates included samples from all
disease subtypes and controls to minimize inter-assay variation. The
same batch of monoclonal antibodies for the Bio-Plex Cytokine AssaySPMS PPMS CIS HC
18 21 17 21
12/6 12/9 14/3 13/8
52 (44–55) 58 (51–65) 34 (28–42) 42 (28–57)
) 19.0 (14.2–25.6) 16.2 (12.2–20.0) 1.0 (0.8–2.2) –
29 (24–35) 40 (35–43) 33 (26–39) –
13.2 (12.2–23.3) 11.2 (4.5–16.5) – –
0.5 (0.3–1.9) 0.4 (0.2–0.9) – –
4.5 (3.0–6.1) 5.5 (3.5–6.3) 0 (0.0–0.0) –
6.0 (3.5–6.0) 6.0 (2.8–6.5) 0 (0.0–0.0) –
16 NA 4 –
1 NA 11 –
1 NA 2 –
16 NA 15 –
1 NA 2 –
0 NA 0 –
17/1/0 21/0/0 17/0/0 –
17/0/0 17/0/0 14/3/0 –
122
ssive MS, PPMS primary progressive MS, CIS clinically isolated syndrome, HC healthy
no treatment.
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intra-assay values are reported to be less than 15% by themanufacturer.
The percent recovery of standards ranged from 90% to 110% that was
used as a detection limit for each protein. The lower detection limits
were as follows: 12.2 pg/ml for sFas, sFasL and MIF, 16.0 pg/ml for
CXCL10, CCL3 and CCL4, 3.2 pg/ml for CCL2, 0.13 pg/ml for IL-10, TNF-α,
IL-6, IL-12p70, IL-2 and IFN-γ.2.3. MRI: image segmentation and volumetric analysis
All examinations were performed on a 1.5 Tesla MRI Unit (Siemens
Avanto, Erlangen, Germany). The MRI protocol for this examination
included a T1 weighted header followed by an axial T1- weighted
magnetization prepared rapid gradient echo (MP-RAGE), and a T2-
weighted turbo spin-echo (TSE), ﬂuid attenuation inversion recovery
(FLAIR), magnetization transfer contrasts (MTC), diffusion weighted
imaging (DWI), and gadolinium enhanced T1 weighted MP-RAGE
sequences. In this study, T1weightedMP-RAGE, FLAIR and T2-weighted
TSE imageswereused for volumetric analysis. ForMP-RAGE, the imaging
parameters were as follows: repetition time (TR)=1160 ms; echo time
(TE)=4.24 ms; inversion time (TI)=600ms; slice thickness=0.9 mm;
in-plane resolution=0.45*0.45 mm. In FLAIR, the following parameters
were used: TR=8500 ms; TE=100 ms; TI=2500 ms; slice thickness=
5.0 mm; in-plane resolution=0.45*0.45 mm. In TSE, the following
imaging scheme was used: TR=750ms; TE=115ms; slice thick-
ness=3.0 mm; in-plane resolution=0.90*0.90 mm. Volumetric seg-
mentation of plaques in the brain was performed using semiautomatic
software Anatomatic™ operating in a PC/Window 95 environment
(Heinonen et al., 1998b, Heinonen et al., 1998a) and the images were
analyzed blindly.2.4. Statistics
Since the immunological data were not normally distributed, the
values were tested by non-parametric analyses: the Kruskal–Wallis
test for comparison of more than two unpaired groups, the Mann–
Whitney U Test for comparison of two unpaired groups, and the
Wilcoxon test for paired groups. Spearman's correlation coefﬁcient
was used to explore the correlation between clinical parameters and
the levels on different proteins. Due to the multiple comparisons, the
criterion for statistical signiﬁcance was p-value less than 0.01.Table 2
The levels (pg/ml) of soluble molecules in different types of MS and controls [median (25t
Molecule CDMS N=72 RRMS N=33 SPMS N=18
sFas 5394.3 (4343.7–6833.5) 4612.8 (4058.0–5940.7)d 5572.4 (4388.3–6845.4
sFasL 94.1 (67.6–168.6) 90.6 (58.1–161.6) 96.2 (72.8–153.6)
MIF 195.0 (100.2–298.0)a 138.2 (50.0–229.4)b,d 225.8 (134.0–317.3)
sTRAIL 845.2 (645.2–1603.0) 765.9 (577.2–1728.9) 785.5 (587.2–1106.0)
CXCL10 98.9 (66.1–154.7) 95.7 (68.1–155.6) 90.5 (62.8–152.6)
CCL2 218.3 (154.7–371.4) 177.0 (140.4–271.8) 218.8 (157.0–331.0)
CCL3 50.9 (22.4–99.3) 37.3 (21.6–96.3) 55.7 (19.2–121.4)
CCL4 160.6 (24.6–835.5) 126.6 (20.4–668.0) 140.2 (17.0–873.8)
IL–10 3.2 (1.6–7.1) 2.9 (0.6–5.7) 3.4 (1.8–7.7)
TNF–α 4.7 (3.7–7.3)a 4.5 (3.4–6.5)d 4.1 (3.3–5.8)
IL–6 7.0 (2.1–18.4) 4.9 (2.0–21.5) 7.1 (3.2–13.0)
IL–12p70 0.6 (0.1–3.0) 0.4 (0.1–1.4) 1.3 (0.4–5.4)
IFN-γ 0.6 (0.3–3.5) 0.3 (0.3–3.0) 1.5 (0.3–4.1)
IL-2 0.6 (0.2–3.6) 1.2 (0.2–3.6) 0.6 (0.2–5.2)
CDMS clinically deﬁniteMS (RRMS, SPMS and PPMS), RRMS relapsing remittingMS, SPMS se
HC healthy controls.
a Comparison between CDMS and HC group, the Mann–Whitney U Test pb0.01.
b Comparison between RRMS and HC group, the Mann–Whitney U Test pb0.01.
c Comparison between PPMS and HC group, the Mann–Whitney U Test pb0.01.
d Comparison between the PPMS and RRMS group, the Mann–Whitney U Test pb0.01.3. Results
3.1. Clinical follow-up data
RRMS patients had a lower EDSS score than the patients with SPMS
and PPMS (Table 1). At one-year follow up, the EDSS score had
increased in 8 out of 30 (27%) RRMS patients, in 6 out of 17 (35%)
SPMS patients, and 6 out of 17 (35%) of patients with PPMS. Two years
before enrollment, 7 of the 33 (21%) RRMS patients were relapse-free,
11 (33%) patients had had one relapse and the remaining 15 (45%)
patients had had 2 to 3 relapses. Over the one-year follow up, 18 of 30
(60%) RRMS patients were relapse-free, 9 (30%) patients had one
relapse and 3 (10%) patients had two to three relapses. Initially, 20 of
72 (28%) CDMS patients were treated with IFN-β and three with
glatiramer acetate (GA) (4%). During the follow up, four patients did
not respond to treatments and, therefore, two IFN-β and one GA
treatments were discontinued and one IFN-β treatment was changed
to GA. In addition, two untreated RRMS patients started IFN-β therapy
due to active disease.
In 17 CIS patients, the time since the ﬁrst demyelinating event
suggestive of MS ranged from 1 to 8 years (median 1 year). Their EDSS
score at the baselinewas 0 except for one subject who had a score of 1.
Four of the seventeen patients were symptom-free two-years
preceding study entry. An elevated IgG index and OCB were found
in 10 CIS patients. Over the one-year period, the EDSS score increased
in two CIS patients and three of them converted into CDMS.
3.2. The levels of cytokines, chemokines and apoptotic molecules at
baseline
The baseline levels of chemokines, inﬂammatory cytokines, and
apoptotic molecules in MS patients and controls are shown in Table 2.
Decreased MIF and elevated TNF-α levels were detected in the CDMS
group (including all MS patients except those with CIS) when compared
to controls (MIF: 195.0 vs. 378.5 pg/ml, pb0.001; TNF-α: 4.7 vs. 3.7 pg/ml,
p=0.005). Comparisons between respective subtypes and controls
revealed a decreased MIF in RRMS (138.2 vs. 378.5 pg/ml, pb0.001)
and increased sFas, TNF-α and CCL2 levels in PPMS (sFas: 6787.6 vs.
4824.9 pg/ml, p=0.01; TNF-α: 6.4 vs. 3.7 pg/ml, pb0.001; CCL2: 288.4 vs.
152.8 pg/ml, p=0.005, Table 2). Further comparison between MS
subtypes revealed higher MIF, TNF-α and sFas in PPMS than in
RRMS (MIF: 290.7 vs. 138.2 pg/ml, p=0.001; TNF-α: 6.4 vs. 4.5 pg/ml,
p=0.010; sFas: 6787.6 vs. 4612.8 pg/ml, p=0.002). The levels ofh–75th percentiles)].
PPMS N=21 CIS N=17 HC N=21
) 6787.6 (5393.9–7709.2)c,d 4318.8 (3320.0–5697.9) 4824.9 (3405.1–5638.1)c
111.2 (71.5–191.9) 83.6 (67.1–174.6) 80.4 (56.6–129.1)
290.7 (189.3–449.3)d 167.3 (97.8–268.2) 378.5 (236.4–535.9)a,b
1032.0 (762.8–2036.1) 902.3(593.3–1170.5) 738.7 (523.2–2260.8)
106.9 (74.7–212.9) 65.9 (53.6–178.2) 106.9 (55.1–130.7)
288.4 (201.3–461.6)C 248.3 (165.7–332.0) 152.8 (122.6–273.1)c
45.4 (27.0–164.7) 72.6 (32.0–186.1) 51.4 (27.7–122.8)
290.7 (39.8–1054.6) 365.1 (144.0–1188.5) 289.1 (16.8–725.0)
3.6 (2.2–9.2) 4.8 (1.2–25.9) 2.3 (0.2–6.0)
6.4 (4.4–8.9)c,d 4.6 (3.5–6.6) 3.7 (2.4–4.6)a,c
8.8 (1.6–26.7) 3.6 (1.4–17.9) 4.1 (2.0–9.3)
0.8 (0.1–4.5) 1.7 (0.3–9.1) 1.6 (0.1–7.9)
0.6 (0.3–3.3) 2.8 (0.3–25.5) 0.5 (0.3–7.5)
0.4 (0.2–2.4) 1.5 (0.5–6.2) 2.1 (0.2–6.1)
condary progressive MS, PPMS primary progressive MS, CIS clinically isolated syndrome,
Fig. 1. Association between EDSS score and the levels of MIF and sFas in CDMS group.
(A) correlations between baseline EDSS and the levels of MIF in clinically deﬁnite MS
(CDMS) group. (B–C) increased levels of sFas and MIF were found in patients with
disability progression in CDMS group. CDMS patients were divided into two groups:
patients with disability progression (EDSS score increased more than 0.5, n=20) and
those without progression of disability (EDSS score unchanged, n=44) over 1 year
follow-up. The length of the box represents the interquartile range within which 50% of
the values were located. The line through the middle of each box represents the
median. The error bars show the minimum and maximum values (range).
144 S. Hagman et al. / Journal of Neuroimmunology 234 (2011) 141–147chemokines CCL3, CCL4, CXCL10, cytokines IL-2, IL-10, IL-6, IL-12p70 IFN-
γ or the apoptotic molecules sFasL and sTRAIL did not differ between the
groups (pN0.01). Nineteen IFN-β treated RRMS patients had increased
levels of CXCL10 compared to 11 untreated patients (median 56.0 vs.
112.6 pg/ml, p=0.001).
3.3. Relation of immunological proﬁles to clinical characteristics
The association of baseline immunological ﬁndings with disease
activity or progression was studied by correlating the levels of
different molecules with the patients' EDSS scores, progression index
and disease activity at baseline and after one year. In the CDMS group,
only baseline MIF (r=0.39, p=0.001, n=72) correlated with the
EDSS score (Fig. 1A), but within the subtypes statistically signiﬁcant
correlations were not found. Over one year, the EDSS score had
increased in 20 out of 64 CDMS patients. To further analyze the
association between immune molecules and disease progression over
the 1 year, CDMS patientswere divided into two groups: patientswith
disability progression (EDSS score increased more than 0.5, n=20)
and those with stable EDSS (EDSS score unchanged, n=44). In the
worsening patients, the levels of sFas (6353.4 0 vs. 4993.2 pg/ml,
p=0.019) and MIF (272.4 vs. 158.3 pg/ml, p=0.020) were higher
than in the stable group (Fig. 1B and C), but no associations were
found between the molecules and the progression index or disease
activity as expressed by the number of relapses.
3.4. Volumes of T1 and FLAIR lesions
At baseline, the volumes of MS plaques were determined in the 89
patients (33 RRMS, 18 SPMS, 21 PPMS, 17 CIS), and over 1 year in 81
(29 RRMS, 17 SPMS, 17 PPMS, 17 CIS) of them. The baseline median
volumes for T1 hypointense and FLAIR-weighted plaques were
1.6 cm3 and 4.9 cm3 in the CDMS group respectively (Table 3). The
T1 lesions represent axonal loss and appear to contribute to
neurological disability and the FLAIR lesions represent a total estimate
of both the active and chronic inﬂammatory plaques especially in the
supratentorial region (Tomassini and Palace, 2009). The volumes of T1
and FLAIR lesions tended to be lowest in PPMS, although the
differences between the subtypes did not reach statistical signiﬁcance
(pN0.01). In CIS patients, the volumes of T1- and FLAIR-lesions were
smaller than in the CDMS group (T1: 0.3 vs. 1.6 cm3, pb0.001 and
FLAIR: 1.1 vs. 4.9 cm3, pb0.001). During the one-year follow up, the
most marked change (Δ) in the T1- lesion volume was seen in SPMS
(ΔT1=1.7 cm3, p=0.018), while the volumes of FLAIR-weighted
plaques increased in allMS subtypes (ΔFLAIR, RRMS: 2.8 cm3, p=0.002,
SPMS: 5.3 cm3, p=0.007, PPMS: 3.2 cm3, p=0.002). No changes were
seen in the volumes of FLAIR lesion in CIS (ΔFLAIR=0.5 cm3, p=0.02).
3.5. Relation of immunological ﬁndings to volumetric MRI measurements
To study the association between immunological molecules and
MRI measurements at the baseline, the levels of chemokines,
cytokines and apoptotic proteins were correlated to volumes of T1
and FLAIR lesions at baseline. In the CDMS group, no associationswere
found between the volumes of T1 or FLAIR lesions and soluble
molecules. However, in the combined group of patients with RRMS
and SPMS, signiﬁcant correlation was detected between the levels of
IL-6 and the volumes of FLAIR lesions (r=0.368 p=0.009, n=51)
(Fig. 2A).
In spite of the increase in FLAIR lesion volumes in the CDMS group
over one year, correlations between immunological and MRI ﬁndings
were not detected. To further evaluate the association between
immunological responses and MRI changes consistent with neurode-
generation, the patients with RRMS and SPMS were divided into two
groups: those with increased volumes of T1 over 1 year (progressed,
ΔT1≥1.0 cm3, n=19) and stable ones (stable, ΔT1b1.0, n=27).Upregulated levels of sFas were found in patients with increasing T1
lesion volumes (5973.8 vs. 4408.1 pg/ml, p=0.010) in comparison
with the stable group (Fig. 2B).
4. Discussion
In this study, the proﬁles of major cytokines, chemokines, and
apoptotic molecules that are thought to be involved in the
pathophysiology of MS were correlated with clinical and MRI
follow-up characteristics with the aim of identifying the biomarkers
of disease activity and progression in MS. Higher levels of sFas, TNF-α
and CCL2 in sera of PPMS patients at baseline in comparison to healthy
controls indicate the presence of inﬂammatory activity in this subtype
where neurodegenerative changes were previously considered to
Table 3
The volumes of T1 and FLAIR lesions in MS subtypes [median (25th–75th percentiles)].
MRI volumes CDMS
N=72
RRMS N=33 SPMS N=18 PPMS N=21 CIS N=17
Number of patients, baseline/1-year 72/64 33/29 18/17 21/17 17/17
T1 (cm3)
Baseline 1.6 (0.5–4.2)⁎ 1.0 (0.4–3.2) 2.9 (1.5–8.4) 1.3 (0.4–5.3) 0.3(0.1–1.2)⁎
1-year 2.6 (0.8–6.7) 1.9 (0.7–4.8) 5.8 (2.6–8.6) 0.8 (0.6–3.1) 0.5 (0.2–0.9)
Δ T1⁎⁎ 0.4 (−0.2–1.6) 0.3(−0.2–1.2) 1.7 (0.0–3.4)⁎⁎⁎ 0.2 (−0.5–0.6) 0.0 (−0.3–0.4)
FLAIR (cm3)
Baseline 4.9 (2.0–15.5)⁎ 3.4 (1.7–11.4) 13.4 (4.1–20.1) 4.6 (1.8–14.5) 1.1 (0.4–2.9)⁎
1-year 11.2 (3.1–22.1) 8.7 (2.5–17.5) 19.2 (10.4–27.6) 5.4 (3.3–12.7) 2.3 (1.0–6.0)
Δ FLAIR⁎⁎ 3.6 (0.8–9.0)⁎⁎⁎ 2.8 (0.7–10.0)⁎⁎⁎ 5.3 (0.8–14.6)⁎⁎⁎ 3.2 (1.2–6.3)⁎⁎⁎ 0.5 (0.4–1.9)
CDMS clinically deﬁnite MS group (RRMS, SPMS and PPMS), RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, CIS clinically isolated
syndrome, FLAIR ﬂuid attenuation inversion recovery.
⁎ Comparison between CIS and CDMS group, the Mann–Whitney U Test pb0.01.
⁎⁎ Changes of MRI volumes from baseline to 1-year follow-up.
⁎⁎⁎ Comparison between the MRI volumes from the baseline to 1-year follow-up, the Wilcoxon test pb0.01.
145S. Hagman et al. / Journal of Neuroimmunology 234 (2011) 141–147prevail over inﬂammation (Frischer et al., 2009, Bradl and Lassmann,
2009, Lassmann et al., 2007). In line with this concept are the results
from the clinical trial on the efﬁcacy of Rituximab in PPMS indicating
delayed time to conﬁrm disease progression in Rituximab-treated
patients with disease activity on MRI (Hawker et al., 2009). The
involvement of the Fas-FasL system in the pathogenesis of MS has
been suggested by several authors (Zipp, 2000, Pender, 2007).
In particular, death receptor Fas defects have been reported in theFig. 2. Association between the volumes of lesions and the levels of IL-6 and sFas in group
comprising RRMS and SPMS patients. (A) statistically signiﬁcant correlation was found
between the volume of FLAIR lesion and the levels of IL-6 in RRMS and SPMS patients.
(B) upregulated levels of sFaswere found in those RRMSand SPMSpatientwhoseT1 lesion
volumes increased in comparison to stable group of patients. RRMS and SPMS patients
were divided in to two groups: those who increased the volumes of T1 from baseline to
one-year follow-up (progressed, n=19) and those with unchanged T1 volumes (stable,
n=27). The length of the box represents the interquartile range within which 50% of the
values were located. The line through the middle of each box represents the median. The
error bars show the minimum and maximum values (range).T lymphocytes of MS patients, and especially in the chronic
progressive subtype. These defects were considered to promote the
survival of autoreactive T cells (Comi et al., 2000, Sharief, 2000). The
soluble forms of Fas have been shown to inhibit apoptotic events in
T cells (Aktas et al., 2006). Our observation of increased sFas in PPMS
is in line with previous data thus favoring the concept of dysregulated
Fas-mediated apoptosis in MS (Ciusani et al., 1998, Boylan et al.,
2001). In addition, TNF-α and CCL2 have been identiﬁed in active MS
lesions (Selmaj et al., 1991) and increased levels of TNF-α in sera and
CSF together with intrathecal synthesis of CCL2 have been reported in
PPMS (Sharief and Hentges, 1991, Hohnoki et al., 1998).TNF-α is a
well-known trigger of the apoptosis of oligodendrocytes (Watzlawik
et al., 2010), while CCL2 is involved in the recruitment of monocytes
and T cells from blood to brain parenchyma (Mahad and Ransohoff,
2003). Taken together, our ﬁndings of increased levels of sFas, TNF-α
and CCL2 in sera of PPMS patients together with earlier evidence are
consistent with the involvement of these molecules in the pathogen-
esis of this subtype.
Lower levels of serum MIF in RRMS as compared to PPMS and
controls are in contrast to earlier data that have shown upregulated
MIF in blood and CSF duringMS relapse (Niino et al., 2000, Rinta et al.,
2008). Calandra et al. have shown that MIF is released from
cytoplasmic stores following stimulation by endotoxin, exotoxin and
cytokines such as TNF and IFN-γ and it can act in an auto and
paracrine fashion to stimulate its own synthesis and the synthesis of
other proinﬂammatory mediators (Calandra et al., 1994). Studies
using experimental autoimmune encephalomyelitis (EAE) have
shown that MIF induces the accumulation of encephalitogenic T
cells in the CNS thus facilitating the development of EAE (Denkinger et
al., 2003, Kithcart et al., 2010). More recently MIF was identiﬁed as a
non-cognate ligand of the chemokine receptors CXCR2 and CXCR4
(Bernhagen et al., 2007). Taken together, these observations suggest
that MIF is associated with disease activity and can potentiate effects of
other proinﬂammatory stimuli. Decreased levels of MIF found in our
RRMS most likely are explained by clinically stable disease, although
their FLAIR lesions volumes increased over 1 year indicating the
presence of persistent inﬂammation in the CNS. The discrepancy
between these clinical and radiological observations are most likely
explained by the fact thatMRI is extremely sensitive for detecting new
inﬂammatory activity in the CNS that is often clinically silent
(Barkhof, 2002). Correlation analyses between the immunological
ﬁndings and MRI measurements showed a positive correlation only
between the serum IL-6 and the baseline volumes of FLAIR lesions in
the RRMS and SPMS groups indicating the role of IL-6 in neuroin-
ﬂammation. IL-6 expression is upregulated under inﬂammatory
conditions and it has a variety of immunoregulatory functions
including differentiation of Th17 cells (Afzali et al., 2010).
146 S. Hagman et al. / Journal of Neuroimmunology 234 (2011) 141–147During the follow up, the levels of sFas increased in those patients
whose EDSS score and T1 lesion volumes increased. T1 lesions
represent axonal loss that contributes to the neurological disability in
MS (Tomassini and Palace, 2009). Evidence on the predictive value of
Fas in the evaluation of disease course has been contradictory (Zipp et
al., 1998, Lopatinskaya et al., 2006). One study reported association
between the increased levels of sFas in sera of patients with short-
term disease progression (Zipp et al., 1998), while a recent 10-year
follow-up study reported an association between increased blood
mRNA expression with favorable disease course in RRMS and SPMS
(Lopatinskaya et al., 2006). Our observations of increased sFas in
worsening patients support the concept of sFas promoting auto-
reactive T cell survival that in turn is likely to facilitate neurodegen-
erative events. Likewise, the positive correlation between MIF and
EDSS scores in the MS group suggests the involvement of MIF in the
neurodegeneration that is further supported by the ﬁnding of
increased MIF in patients with disability progression over 1 year.
In summary, according to our data, Fas and MIF may be considered
candidate biomarkers of disease progression in MS. However, although
TNF-α and CCL2 seem to reﬂect MS-related inﬂammatory responses,
especially in PPMS, their role as biomarkers of clinical disease activity
remains to be evaluated in a long-term study involving a larger patient
cohort.
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Is the modulatory eﬀect of pregnancy in
multiple sclerosis associated with changes in
blood apoptotic molecules?
Introduction
The annualized relapse rate (ARR) of multiple
sclerosis (MS) declines during the third trimester of
pregnancy, but increases again during the ﬁrst
3 months post-partum before returning to the
prepregnancy rate (1). This effect of pregnancy
on MS disease activity has been explained by
changes in the mothers endocrinal and immune
system and is characterized by an increase in the
levels of the sex hormones estrogen and progester-
one together with a shift of maternal immune
responses from a prevailing T-helper cell (Th)1
responses to a Th2-type response. An increase in
regulatory cytokines interleukin (IL)-4 and IL-10
together with downregulation of proinﬂammatory
cytokines interferon (IFN)-c and IL-2 in women at
late pregnancy (2–6) has been reported. Based on in
vitro evidence, increased levels of estrogens can
inhibit expression of proinﬂammatory cytokines
IL-6, IL-8 and tumor necrosis factor (TNF)-a and
stimulate expression of regulatory cytokines IL-10,
IL-4 and transforming growth factor (TGF)-b (7).
It is proposed that a shift in maternal immune
responses from a prevailing Th1 response to a Th2-
type response is necessary for protecting the
developing fetus (4, 8). Interestingly, a decrease
of circulating natural killer (NK) cells and an
increase of regulatory T cells during pregnancy has
been associated with reduced MS disease activity
(9, 10). Moreover, an increase in circulating
regulatory CD56 (bright) NK cells and a decrease
of circulating cytotoxic CD56 (dim) NK cells in
late pregnancy was considered to be associated
with inhibition of MS activity during pregnancy
(11).
Although understanding of the amelioration of
MS during pregnancy has improved recently, the
exact mechanism of this phenomenon still remains
obscure (12). Upregulation of soluble apoptotic
molecules including TNF-related apoptosis-indu-
cing ligand (sTRAIL), Fas ligand (sFasL) and
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macrophage migration inhibitory factor (MIF) has
been related to immune activation in MS (13), but
it is not known whether changes in the levels of
these proteins are associated with modulation of
MS during pregnancy. To answer this question, we
analyzed the levels of sTRAIL, sFas, sFasL and
MIF in sera of pregnant women with MS at late
pregnancy and post-partum and related the
obtained data to ARR and Expanded Disability
Status Scale (EDSS) score.
Patients and methods
Patients
The study included 19 pregnant patients with
relapsing remitting MS (RRMS) and 14 pregnant
healthy controls (Table 1). The mean (SE) age
of RRMS patients at early pregnancy was
30.1  0.7 years and in controls 30.1  1.1 years.
Patient recruitment and neurological examinations
were performed as reported previously (11).
Patients underwent neurological examination at
10–12 weeks of pregnancy (early pregnancy),
26–28 weeks of gestation (late pregnancy) and
6 months post-partum. Clinical characteristics
(mean  SE) of the patients at the beginning of
the study are given in Table 1. At the beginning
of the study the duration of MS from the time of
diagnosis was 5.7  0.9 years (range 0–13), the
total number of relapses was 4.1  0.7 (range 0–12
relapses) and EDSS was 1.1  0.2. Before preg-
nancy six patients were treated with IFN-b
(Rebif, Merck Serono S.A., Modugno, Italy,
n = 2; Betaferon, Bayer Schering pharma AG,
Berlin, Germany, n = 3; and Avonex, Biogen Idec
BV, Hoofddorp, Netherlands, n = 1) and three
patients with glatiramer acetate (Copaxone, Teva
Pharmaceuticals Europe B.V., Utrecht, Nether-
lands). In most of the patients the medication was
discontinued before pregnancy, and only three
patients continued on immunomodulatory treat-
ment until the ﬁrst month of pregnancy.
Blood sample collection
The blood fromMS patients was drawn during late
pregnancy and 3 (n = 16) or 6 (n = 3) months
after delivery, whereas the sera from healthy
pregnant women (n = 14) were collected during
late pregnancy and 3 months post-partum.
The cytokine determinations
The levels of sFas, sFasL and MIF in sera were
measured simultaneously with a Human Apoptosis
Lincoplex Kit (Linco Research, St Charles, IL,
USA) and sTRAIL levels were measured using an
ELISA kit (Diaclone, Besancon Cedex, France) as
previously reported (13).
Statistical analyses
Statistical analyses were performed using SPSS
version 16.0 for Windows (SPSS Inc., Chicago, IL,
USA). The numbers of relapses a year before
pregnancy, during pregnancy and 6 months post-
partum follow-up were converted to a relapse rate
per patient per year (ARR). The changes of
diﬀerent parameters (DARR, DEDSS, DTRAIL,
DFas, DFasL and DMIF) at diﬀerent time points
were also studied. Comparisons between pre- and
post-partum ARR, EDSS and levels of these
molecules were performed using the Wilcoxon
test, and comparison between MS patients and
controls, and active and stable patients by the
Mann–Whitney test. A P-value less than 0.05 was
considered statistically signiﬁcant. Correlations
between variables were tested by two-tailed
non-parametric Spearman correlation analysis.
Owing to multiple correlation testing, a P-value
of less than 0.01 was considered signiﬁcant.
Table 1 Patients demographics at the onset of the study
Characteristics MS (n = 19) Controls (n = 14)
Age (years)a 30.1  0.7 30.1  1.1
Duration of disease (years)a 5.7  0.9 NA
Number of relapsesa,b 4.1  0.7 NA
EDSS at initiationa,c 1.1  0.2 NA
DMT before pregnancyd 9 NA
Rebif 3 NA
Betaferon 3 NA
Copaxone 3 NA
DMT during 1–6 months PPd 9 NA
Rebife 5 NA
Betaferon 1 NA
Avonex 1
Copaxonee 2 NA
Gestational weeksa 40.1  0.32 NA
Breastfeedingd 17 NA
Blood sample collectiond 19 14
During late pregnancyd 19 14
During 3 ⁄ 6 months PPd 16 ⁄ 3 14
aMean  SE.
bTotal number of relapses experienced before the onset of the study.
cEDSS for pregnant patients at 10–12 gestational weeks.
dNumber of patients.
eRebif was initiated in two patients and Copaxone was initiated in one patient
before post-partum sampling.
MS, multiple sclerosis; EDSS, Expanded Disability Status Scale; DMT, disease-
modifying therapy; PP, post-partum; NA, not available.
Modulatory effect of pregnancy in MS
169
Results
Activity of MS during and after pregnancy
Comparison between the means (SE) of ARR
before and during pregnancy revealed a decrease in
ARR from prepregnancy situation to pregnancy
(0.9  0.2 to 0.4  0.2 relapses ⁄woman ⁄year;
P = 0.004; Table 2), but the change between the
ARRs before pregnancy and post-partum was not
signiﬁcant (0.9  0.2 vs 1.5  0.3 relapses ⁄
woman ⁄year; P = 0.10). Comparison between
ARRs during and after pregnancy showed a
statistically signiﬁcant increase in ARR after preg-
nancy (0.4  0.2 vs 1.5  0.3 relapses ⁄woman ⁄ -
year, P = 0.01). Fifteen out of the 19 MS patients
were relapse-free during pregnancy, 3 patients had
a relapse during the ﬁrst or second trimester and
only 1 patient experienced a relapse during the
third trimester. During the 6-month post-partum
follow-up, 7 patients remained relapse-free and 12
patients had 1–3 relapses. The majority (8 of 12) of
the post-partum relapses occurred during the ﬁrst
3 months after pregnancy.
The mean (SE) EDSS tended to increase
during the 6-months post-partum follow-up, but
the diﬀerences between EDSS at diﬀerent timings
were not statistically signiﬁcant (1.1  0.2 vs
1.2  0.2 vs 1.5  0.2; P > 0.05; Table 2). Four
patients were prescribed immunomodulatory treat-
ment during the ﬁrst 3 months post-partum, and in
5 patients the treatment was started between 3 and
6 months post-partum.
The levels of apoptosis-related molecules during late pregnancy
and after pregnancy
The levelsof sTRAIL,sFasL, sFasandMIFinserum
samples obtained pre- and post-partum from 19MS
patients and 14 controls are shown in Fig. 1. A
signiﬁcant increase in the levels (mean  SE) of
sTRAIL and sFasL was seen from pre- to post-
partum periods in both patients with MS (sTRAIL:
0.38  0.07 vs 0.72  0.11 ng ⁄ml, P = 0.002 and
sFasL:0.30  0.11vs0.35  0.12 ng ⁄ml,P =0.02)
and their controls (sTRAIL: 0.76  0.13 vs
1.51  0.25 ng ⁄ml, P = 0.004 and sFasL: 0.16 
0.04 vs 0.25  0.05 ng ⁄ml, P = 0.003). Moreover,
serum sTRAIL levelswere lower in patientswithMS
than in healthy controls both in the pre- and post-
partum situations (sTRAIL prepartum: MS 0.38 
0.07 vs control 0.76  0.13 ng ⁄ml, P = 0.0005 and
sTRAIL post-partum: MS 0.72  0.11 vs control
1.51  0.25 ng ⁄ml, P = 0.002). The changes (D) in
the levels of sTRAIL ()0.33  0.11 vs )0.75 
0.19 ng ⁄ml, P = 0.05) from late pregnancy to
post-partum were smaller in MS patients than in
controls(Fig. 2).Nochangeswereseeninthelevelsof
sFasL between MS and controls ()0.05  0.02 vs
)0.09  0.08 ng ⁄ml,P = 0.161).
Over the pre- to post-partum periods the levels of
sFasandMIFtendedtodecreaseboth inMSpatients
(sFas: 4.57  0.29 vs 3.96  0.40 ng ⁄ml, P = 0.08
and MIF: 0.96  0.19 vs 0.72  0.15 ng ⁄ml,
P = 0.12) and their controls (sFas: 4.88  0.19 vs
4.19  0.20 ng ⁄ml,P = 0.03andMIF:1.19  0.40
vs 0.51  0.10 ng ⁄ml, P = 0.06), but the diﬀerence
between D values was not statistically signiﬁcant in
these groups (Fig. 2; DsFas: 0.61  0.32 vs
1.19  0.56 ng ⁄ml, P = 0.560 and DMIF:
0.24  0.16 vs 0.67  0.40 ng ⁄ml, P = 0.500).
Comparisons between the levels of apoptotic
proteins in pre- and post-partum samples were also
performed in the subgroup of 15 patients in whom
disease-modifying therapy was not initiated before
post-partum sampling (Table 1). The analyses
revealed upregulation of sTRAIL (0.33  0.04 vs
0.54  0.30 ng ⁄ml, P = 0.001) and sFasL
(0.32  0.12 vs 0.38  0.13 ng ⁄ml, P = 0.02)
after delivery. The change (D) in TRAIL levels
from late pregnancy to post-partum was smaller in
untreated MS patients than in controls
()0.20  0.05 vs )0.75  0.19 ng ⁄ml, P = 0.012),
but the diﬀerences between the DsFas (0.56  0.35
vs 1.19  0.56 ng ⁄ml, P = 0.484), DsFasL
()0.05  0.02 vs )0.09  0.02 ng ⁄ml, P = 0.154)
and DMIF (0.32  0.15 vs 0.67  0.40 ng ⁄ml,
Table 2 Multiple sclerosis patients disease activity and neurologic disability before, during and after pregnancy
Before
pregnancy
During
pregnancy
Post-partum P1 P2 P3
Annualized
relapse ratea
0.9 + 0.2 0.4  0.2 1.5  0.3 0.004 0.100 0.010
EDSSa 1.1  0.2b 1.2  0.2 1.5  0.2 0.236 0.253 0.100
aMean  SE.
bEDSS for pregnant patients at 10–12 gestational weeks.
P1 compared between before and during pregnancies; P2 compared between before and after pregnancies; P3 compared between during and after pregnancies; EDSS,
Expanded Disability Status Scale.
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Figure 1. The levels (ng ⁄ml) of tumor necrosis factor-related apoptosis-inducing ligand (A, B), Fas ligand (C, D), sFas (E, F) and
macrophage migration inhibitory factor (G, H) during late pregnancy (prepartum) and after delivery (post-partum) in multiple
sclerosis patients (A, C, E and G) and healthy controls (B, D, F and H). The levels of molecules are shown for each donor. The
arrowhead indicates the mean value.
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P = 0.586) in these groups were not signiﬁcant.
IFN-b (n = 3) and glatiramer acetate (n = 1)
treatmentwas started in the remaining four patients.
Relationship between disease activity and apoptotic proteins
No correlations were found between the levels of
serum apoptotic molecules and ARRs or EDSS
(P > 0.01). Likewise, the changes (D) in the levels of
apoptotic proteins from late pregnancy to post-
partum did not correlate with the changes of ARRs
or EDSS (P > 0.01).
To further explore the relationship between
quantitative changes in the apoptotic molecules
and activity of MS, the patients were divided into
an active group (n = 11, up to three relapses after
pregnancy; 1.36  0.15, mean  SE) and a stable
group (n = 7, no relapses). Comparison between
these groups showed that the patients with active
MS had smaller DFasL from pregnancy to post-
partum than the patients with inactive disease
()0.02  0.06 vs )0.09  0.07 ng ⁄ml, P = 0.04).
The post-partum levels of sTRAIL (P = 0.596),
sFas (P = 0.69), sFasL (P = 0.32) and MIF
(P = 0.67) in active and stable MS patients were
of the same magnitude.
Discussion
In spite of the recent progress in the understanding
of the modulatory eﬀect of pregnancy on MS, very
little is known about the detailed molecular mech-
anisms of this phenomenon (12). Previously, it has
been hypothesized that failure of activation-
induced cell death (apoptosis) of autoreactive T
cells is a major pathogenetic mechanism in MS
(14). Detection of impaired apoptosis of lympho-
cytes or T cells obtained from MS patients (15–18)
is consistent with this hypothesis. Furthermore,
recent studies have shown downregulation of pro-
apoptotic molecules in lymphocytes obtained from
patients with active MS, suggesting abnormalities
in the apoptotic cell death of lymphocytes in MS
(19–21). In the present study we analyzed whether
the beneﬁcial eﬀect of pregnancy on MS is asso-
ciated with quantitative changes of apoptotic
molecules in serum.
The levels of serum sTRAIL and sFasL in MS
patients increased post-partum. Earlier we reported
an association between elevated sTRAIL and dis-
ease activity in RRMS (13). TRAIL is a member of
theTNF superfamily that is expressed inmembrane-
bound and soluble forms from lymphocytes and
monocytes in an activation-dependent manner (22).
It has been shown that sTRAIL inhibits prolifera-
tion of activated T cells (23, 24) and inhibition of
TRAIL outside the central nervous system (CNS)
has been shown to worsen Experimental Auto-
immuneEncephalomyelitis (EAE) (25).However, in
the CNS, TRAIL mediates apoptosis of brain cells
(26–28). In MS, TRAIL has been shown to reﬂect
bioactivity of IFN-b (29). Post-partumupregulation
of sTRAIL in bothMSpatients and controlsmay be
associated with physiological immune activation
known to occur after pregnancy and may reﬂect a
tendency of the immune system to control inﬂam-
matory responses. The smaller increase of sTRAIL
from late pregnancy to post-partum in MS com-
Figure 2. The changes (D) in the levels of tumor necrosis factor-related apoptosis-inducing ligand (A), Fas ligand (B), sFas (C) and
macrophage migration inhibitory factor (D) seen from late pregnancy to post-partum in multiple sclerosis patients and controls
(ng ⁄ml). The levels of molecules are shown for each donor. Horizontal lines indicate the mean values.
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pared with controls, detected by us, may be a factor
associated with activation of MS after delivery.
A signiﬁcant increase in the levels of sFasL was
seen from pre- to post-partum periods in both
patients with MS and their controls. Fas receptor
(CD95) and FasL (CD154) participate in the
apoptotic signaling pathway in the activated
T cells (30). Membrane-bound forms of Fas and
FasL are able to induce apoptosis of T cells, but
soluble forms, in contrast, inhibit apoptotic events
(31, 32). The upregulation of sFasL after preg-
nancy in both MS patients and controls seen in this
study may be associated with increased immune
activation. This is in accordance with our data
showing increased levels of sFasL during MS
relapses (13) and results by other investigators
reporting increased expression of FasL mRNA in
blood cells during lesional activity (33). The similar
levels of sFas in pre- and post-partum samples of
MS patients are consistent with previous data by
Ehrlich et al. (34).
The levels of MIF tended to decrease post-
partum in MS patients and healthy women.
Increased expression of MIF in the blood and
cerebrospinal ﬂuid in patients with MS relapses has
been reported earlier by us and others (13, 35).
MIF is considered to be a pleiotropic cytokine
secreted by lymphocytes and macrophages and its
most critical functions encompass the regulation of
macrophage function, lymphocyte immunity and
endocrine functions (36). MIF induces accumula-
tion of encephalitogenic T cells in the CNS thus
facilitating the development of EAE (37).
Taken together, upregulation of sTRAIL and
sFasL from pregnancy to post-partum situation
both in patients with MS and healthy women is the
major observation of our study. As these molecules
are secreted by immune cells in activation-
dependent manner, it is most likely that the
quantitative changes detected in this study are a
result of T-cell activation occurring during physi-
ological reactivation of mothers immune system
after pregnancy (4, 38). An increased risk for
relapses in MS after delivery may be associated
with changes in immunomodulatory potential of
these apoptotic molecules.
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